Iron Deficiency Anaemia
Assessment, Prevention and Control

A guide for programme managers
Executive summary

This document deals primarily with indicators for monitoring interventions to combat iron deficiency, including iron deficiency anaemia. However, it also reviews the current methods of preventing iron deficiency in the light of recent significant scientific advances. It summarizes regional prevalences of anaemia, and briefly discusses the principal factors affecting its prevalence.

Indicators for assessing iron deficiency are presented, together with their thresholds of abnormality in various age, gender, and physiological status; the relationships between them; and their applicability in different settings according to resource availability.

It also presents approaches for obtaining dietary information and guidance on designing national iron deficiency prevention programmes. Iron requirements and recommended iron intakes from diets of different bioavailability are summarized.

Criteria for defining iron deficiency anaemia are provided, and a slight modification from those previously recommended by WHO is proposed. Also proposed are criteria for defining the public health severity of anaemia, on the basis of prevalence estimates. Acceptable methods for assessing anaemia and iron status, both on the basis of clinical examinations and blood tests, are discussed. Threshold values for the interpretation of these indices are given.

Strategies for preventing iron deficiency through food-based approaches, i.e. dietary improvement or modification and fortification, are discussed. For example, modifiers that affect the bioavailability of food-iron sources are reviewed, and suggestions for altering meal patterns to improve absorbability are offered.

A schedule for using iron supplements to control iron deficiency, and to treat mild-to-moderate IDA according to age, gender, and physiological status, is provided. For each strategy, desirable actions are outlined and criteria suggested for assessment of the intervention. In this connection, indicators for use in monitoring programme implementation are described.
In most countries, some aspects of each of the main types of intervention will be needed to control the problem of iron deficiency. Particular attention is devoted to micronutrient complementarities in programme implementation. For example, the particularly close link between improving iron status and improving vitamin A status is explored.

Finally, recommendations are made for action-oriented research on the control of iron deficiency, and for undertaking feasibility studies on iron fortification in countries. Increased advocacy, exchange of information, development of human resources, and action-oriented research are recommended for accelerating the achievement of the goals for reducing iron deficiency.
# Contents

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>i</td>
<td>Executive summary</td>
<td>iii</td>
</tr>
<tr>
<td>ii</td>
<td>Table of contents</td>
<td>v</td>
</tr>
<tr>
<td>iii</td>
<td>List of tables</td>
<td>viii</td>
</tr>
<tr>
<td>iv</td>
<td>List of figures</td>
<td>ix</td>
</tr>
<tr>
<td>v</td>
<td>Abbreviations</td>
<td>x</td>
</tr>
<tr>
<td>vi</td>
<td>Acknowledgements</td>
<td>xi</td>
</tr>
<tr>
<td>vii</td>
<td>Preface</td>
<td>xii</td>
</tr>
<tr>
<td>1</td>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>Concepts used in defining iron nutritional status</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>Functional consequences of iron deficiency</td>
<td>7</td>
</tr>
<tr>
<td>3.1</td>
<td>Cognitive development</td>
<td>7</td>
</tr>
<tr>
<td>3.2</td>
<td>Resistance to infection</td>
<td>8</td>
</tr>
<tr>
<td>3.3</td>
<td>Work capacity and productivity</td>
<td>9</td>
</tr>
<tr>
<td>3.4</td>
<td>Pregnancy</td>
<td>9</td>
</tr>
<tr>
<td>3.5</td>
<td>Growth</td>
<td>9</td>
</tr>
<tr>
<td>3.6</td>
<td>Endocrine and neurotransmitters</td>
<td>10</td>
</tr>
<tr>
<td>3.7</td>
<td>Heavy-metal absorbtion</td>
<td>10</td>
</tr>
<tr>
<td>4</td>
<td>Economic implications of iron deficiency</td>
<td>11</td>
</tr>
<tr>
<td>5</td>
<td>Prevalence and epidemiology of iron deficiency</td>
<td>15</td>
</tr>
<tr>
<td>5.1</td>
<td>Prevalence</td>
<td>15</td>
</tr>
<tr>
<td>5.2</td>
<td>Epidemiology</td>
<td>17</td>
</tr>
</tbody>
</table>
## Contents (continued)

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Assessment, surveillance, and indicators</td>
<td>23</td>
</tr>
<tr>
<td>6.1</td>
<td>Individual and population-based assessment</td>
<td>23</td>
</tr>
<tr>
<td>6.2</td>
<td>Purposes of biological assessments</td>
<td>24</td>
</tr>
<tr>
<td>6.3</td>
<td>Selection of subjects for assessment</td>
<td>25</td>
</tr>
<tr>
<td>6.4</td>
<td>General issues in defining iron status indicators</td>
<td>26</td>
</tr>
<tr>
<td>6.5</td>
<td>The spectrum of iron nutritional status</td>
<td>27</td>
</tr>
<tr>
<td>6.6</td>
<td>Application of iron-related indicators to specific settings</td>
<td>29</td>
</tr>
<tr>
<td>7</td>
<td>Methods of assessing iron status</td>
<td>33</td>
</tr>
<tr>
<td>7.1</td>
<td>Assessment of anaemia</td>
<td>33</td>
</tr>
<tr>
<td>7.2</td>
<td>Specific tests or procedures for assessing iron status</td>
<td>37</td>
</tr>
<tr>
<td>7.3</td>
<td>Defining iron deficiency when multiple indices are available</td>
<td>41</td>
</tr>
<tr>
<td>7.4</td>
<td>Haemoglobin response to iron and other supplements or interventions</td>
<td>42</td>
</tr>
<tr>
<td>7.5</td>
<td>Assessing population iron status by using haemoglobin distributions</td>
<td>43</td>
</tr>
<tr>
<td>8</td>
<td>Prevention strategies</td>
<td>47</td>
</tr>
<tr>
<td>8.1</td>
<td>Food-based approaches</td>
<td>47</td>
</tr>
<tr>
<td>8.2</td>
<td>Iron supplementation</td>
<td>56</td>
</tr>
<tr>
<td>9</td>
<td>Action-oriented research needs</td>
<td>67</td>
</tr>
<tr>
<td>9.1</td>
<td>Dietary improvement</td>
<td>67</td>
</tr>
<tr>
<td>9.2</td>
<td>Iron fortification</td>
<td>68</td>
</tr>
<tr>
<td>9.3</td>
<td>Iron supplementation</td>
<td>69</td>
</tr>
<tr>
<td>10</td>
<td>General recommendations</td>
<td>71</td>
</tr>
<tr>
<td>10.1</td>
<td>For governments</td>
<td>71</td>
</tr>
<tr>
<td>10.2</td>
<td>For supporting organizations and institutions</td>
<td>72</td>
</tr>
<tr>
<td>References</td>
<td></td>
<td>75</td>
</tr>
</tbody>
</table>
# Contents (concluded)

<table>
<thead>
<tr>
<th>Annex</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>List of participants: IDA Consultation, Geneva</td>
<td>89</td>
</tr>
<tr>
<td>2</td>
<td>The practical significance of iron overload for iron fortification and supplementation programmes</td>
<td>93</td>
</tr>
<tr>
<td>3</td>
<td>Variations in haemoglobin and haematocrit levels</td>
<td>97</td>
</tr>
<tr>
<td>4</td>
<td>Approaches for obtaining information on availability, dietary patterns, and consumption of iron-containing foods</td>
<td>103</td>
</tr>
<tr>
<td>5</td>
<td>Strategies and guidelines for national IDA control programmes</td>
<td>107</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention (USA)</td>
<td></td>
</tr>
<tr>
<td>CSM</td>
<td>Corn-soy-milk</td>
<td></td>
</tr>
<tr>
<td>DALY</td>
<td>Disability adjusted life years</td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>Iron deficiency</td>
<td></td>
</tr>
<tr>
<td>IDA</td>
<td>Iron deficiency anaemia</td>
<td></td>
</tr>
<tr>
<td>EP</td>
<td>Erythrocyte protoporphyrin</td>
<td></td>
</tr>
<tr>
<td>FAO</td>
<td>Food and Agriculture Organization of the United Nations</td>
<td></td>
</tr>
<tr>
<td>G6PD</td>
<td>Glucose-6 phosphate dehydrogenase</td>
<td></td>
</tr>
<tr>
<td>Hb</td>
<td>Haemoglobin</td>
<td></td>
</tr>
<tr>
<td>Hct</td>
<td>Haematocrit</td>
<td></td>
</tr>
<tr>
<td>IDD</td>
<td>Iodine deficiency disorders</td>
<td></td>
</tr>
<tr>
<td>INACG</td>
<td>International Nutritional Anaemia Consultative Group</td>
<td></td>
</tr>
<tr>
<td>IQ</td>
<td>Intelligence quotient</td>
<td></td>
</tr>
<tr>
<td>Na-Fe EDTA</td>
<td>Sodium ferric ethylenediaminetetraacetic acid</td>
<td></td>
</tr>
<tr>
<td>JECFA</td>
<td>Joint FAO/WHO Expert Committee on Food Additives</td>
<td></td>
</tr>
<tr>
<td>MCH</td>
<td>Maternal and child health</td>
<td></td>
</tr>
<tr>
<td>MCHC</td>
<td>Mean corpuscular haemoglobin concentration</td>
<td></td>
</tr>
<tr>
<td>MCV</td>
<td>Mean corpuscular volume</td>
<td></td>
</tr>
<tr>
<td>MDIS</td>
<td>Micronutrient Deficiency Information System</td>
<td></td>
</tr>
<tr>
<td>NGO</td>
<td>Nongovernmental organization</td>
<td></td>
</tr>
<tr>
<td>PHC</td>
<td>Primary health care</td>
<td></td>
</tr>
<tr>
<td>RBC</td>
<td>Red blood cells</td>
<td></td>
</tr>
<tr>
<td>SF</td>
<td>Serum ferritin</td>
<td></td>
</tr>
<tr>
<td>SI</td>
<td>Serum iron</td>
<td></td>
</tr>
<tr>
<td>TIBC</td>
<td>Total iron binding capacity</td>
<td></td>
</tr>
<tr>
<td>TR</td>
<td>Transferrin receptor</td>
<td></td>
</tr>
<tr>
<td>TS</td>
<td>Transferrin saturation</td>
<td></td>
</tr>
<tr>
<td>T&lt;sub&gt;3&lt;/sub&gt;</td>
<td>Triiodothyronine</td>
<td></td>
</tr>
<tr>
<td>UNICEF</td>
<td>United Nations Children’s Fund</td>
<td></td>
</tr>
<tr>
<td>UNU</td>
<td>United Nations University</td>
<td></td>
</tr>
<tr>
<td>VAD</td>
<td>Vitamin A deficiency</td>
<td></td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
<td></td>
</tr>
<tr>
<td>WSB</td>
<td>Wheat-soy blend</td>
<td></td>
</tr>
</tbody>
</table>
The World Health Organization gratefully acknowledges the valuable contributions of the participants in the WHO/UNICEF/UNU consultation (Annex 1). Special thanks are also due to Leif Hallberg, Nevin Scrimshaw, Fernando Viteri and Ray Yip for references to the literature and portions of text, and for reviewing the draft report; and to Ken Bailey and Barbara Underwood, former staff members in the Department of Nutrition for Health and Development, who participated in the document’s early development. Thanks are also due to James Akré, Henrietta Allen, Graeme Clugston and Anna Verster for their contributions. Bruno de Benoist coordinated the overall production of the document, while Ross Hempstead was responsible for editing and layout.
Preface

This document is based in large part on a consultation convened in Geneva from 6-10 December 1993, jointly organized by the World Health Organization (WHO), the United Nations Children’s Fund (UNICEF), and the United Nations University (UNU).

Since the meeting there have been significant new data emerging in key areas, which have been published in scientific literature and presented in international meetings. It was recognized that this information was relevant and should also be included. Therefore, the final text has been updated and contains new material, together with the conclusions reached and recommendations made by the Consultation.

Iron deficiency, and specifically iron deficiency anaemia, remains one of the most severe and important nutritional deficiencies in the world today. Every age group is vulnerable. Iron deficiency impairs the cognitive development of children from infancy through to adolescence. It damages immune mechanisms, and is associated with increased morbidity rates.

During pregnancy, iron deficiency is associated with multiple adverse outcomes for both mother and infant, including an increased risk of haemorrhage, sepsis, maternal mortality, perinatal mortality, and low birth weight. It is estimated that nearly all women are to some degree iron deficient, and that more than half of the pregnant women in developing countries suffer from anaemia. Even in industrialized countries, the iron stores of most pregnant women are considered to be deficient. Finally, as much as a 30% impairment of physical work capacity and performance is reported in iron-deficient men and women.

The economic implications of iron deficiency and of the various intervention strategies to combat it, suggest that food-based approaches and targeted supplementation are particularly cost-effective. The highest benefit-to-cost ratio is attained with food fortification.
In the last two decades, the importance of iron deficiency and anaemia as a public health problem has been increasingly recognized by health authorities and policy makers. This is reflected in the goals on the reduction of iron deficiency anaemia endorsed by Heads of State, ministers in the World Declaration and Plan of Action from the World Summit for Children (1990) and in the World Declaration and Plan of Action for Nutrition from the International Conference on Nutrition (1992).

The document aims at providing scientists and national authorities worldwide with an up-to-date and authoritative review of iron deficiency anaemia, together with guidelines and recommendations. It is also intended for managers of national programmes dealing with the prevention and control of micronutrient malnutrition, as well as for policy makers. It is meant to help them to implement effective measures for fighting iron deficiency anaemia. We hope that the information included in this manual will contribute to our common effort to eliminate iron deficiency anaemia.
Introduction

In 1992, World Health Resolution WHA45.33 urged Member States to:

establish, as part of the health and nutrition monitoring system, a micronutrient monitoring and evaluation system capable of assessing the magnitude and distribution of iodine, vitamin A and iron deficiency disorders, and monitor the implementation and impact of control programmes . . .

For their part, WHO and UNICEF, together with key partners, convened a series of consultations on appropriate indicators for assessing and monitoring micronutrient deficiencies and their control programmes. Consultations on iodine deficiency disorders and vitamin A deficiency were held first, in 1992 (1,2).

A third consultation on iron deficiency was held a year later, in December 1993, providing the basis for the present document. Also included is important new information emerging since the consultation.

Iron deficiency affects a significant part, and often a majority, of the population in nearly every country in the world. Programmes for the prevention of iron deficiency, particularly iron supplementation for pregnant women, are under way in 90 of 112 countries that reported to WHO in 1992 (3). Most of these programmes, however, are neither systematically implemented nor well monitored or evaluated.

Scientific consensus on the prevention of iron deficiency anaemia was described in a 1989 WHO monograph (4). Since then, however, knowledge of the consequences of iron deficiency - even in the absence of anaemia - has evolved, while fortification technology has improved considerably.

Furthermore, national, regional, and global efforts to overcome micronutrient malnutrition have gathered accelerated momentum. As a result, an overall review of the strategies for preventing iron deficiency - together with a closer examination of prevalence indicators and methods of monitoring programmes of prevention - have become appropriate and timely.
The general objective of the 1993 consultation was to review and accelerate global processes for preventing iron deficiency, with the goal of substantially reducing the problem during the forthcoming decade.

The specific objectives of the consultation were as follows:

- To review appropriate target groups for iron deficiency and anaemia assessment and surveillance, and appropriate prevalence indicators, criteria, and thresholds.

- To review and make general recommendations on suitable laboratory methods for assessment of key indicators.

- To identify the steps by which the main strategies - improved food consumption and dietary practices, food fortification, supplementation, and public health measures - could be more effectively implemented at each level.

- To identify appropriate indicators for monitoring programme implementation.

- To identify high-priority, action-oriented, and operational research needed to enable and accelerate effective programme implementation.

- To determine critical needs in human resources development for prevention of iron deficiency.
Iron status can be considered as a continuum from iron deficiency with anaemia, to iron deficiency with no anaemia, to normal iron status with varying amounts of stored iron, and finally to iron overload - which can cause organ damage when severe. Iron deficiency is the result of long-term negative iron balance. Iron stores in the form of haemosiderin and ferritin are progressively diminished and no longer meet the needs of normal iron turnover.

From this critical point onward, the supply of iron to the transport protein apotransferrin is compromised. This condition results in a decrease in transferrin saturation and an increase in transferrin receptors in the circulation and on the surface of cells, including the erythron.

All tissues express their need for iron in exactly the same way, i.e. by the same type of transferrin receptors on cell surfaces in proportion to actual iron need. Accordingly, a compromised supply of iron to the erythron is associated with a similarly insufficient supply of iron to all other tissues.

Functionally, the lack of mobilizable iron stores will eventually cause a detectable change in classical laboratory tests, including measurement of haemoglobin, mean corpuscular haemoglobin concentration, mean corpuscular volume, total iron-binding capacity, transferrin saturation, and zinc-erythrocyte protoporphyrin.

Iron deficiency is defined as a condition in which there are no mobilizable iron stores and in which signs of a compromised supply of iron to tissues, including the erythron, are noted. The more severe stages of iron deficiency are associated with anaemia.

When iron-deficient erythropoiesis occurs, haemoglobin concentrations are reduced to below-optimal levels. When individual haemoglobin levels are below two standard deviations (-2SD) of the distribution mean for haemoglobin in an otherwise normal population of the same gender and age who are living at the same altitude, iron deficiency anaemia is considered to be present.
IRON DEFICIENCY ANAEMIA

In a normal population, 2.5% of the population would be expected to be below this threshold. Hence, iron deficiency anaemia would be considered a public health problem only when the prevalence of haemoglobin concentration exceeds 5.0% of the population (see Table 3).

The prevalence of iron deficiency anaemia in a population is therefore a statistical rather than a physiological concept, although it reflects that proportion of the population that has iron-deficient erythropoiesis. Iron deficiency anaemia should be regarded as a subset of iron deficiency. That is, it represents the extreme lower end of the distribution of iron deficiency.

Because anaemia is the most common indicator used to screen for iron deficiency, the terms anaemia, iron deficiency, and iron deficiency anaemia are sometimes used interchangeably. There are, however, mild-to-moderate forms of iron deficiency in which, although anaemia is absent, tissues are still functionally impaired.

In addition, although iron deficiency anaemia accounts for most of the anaemia that occurs in underprivileged environments, several other possible causes should be noted. These include haemolysis occurring with malaria; glucose-6-phosphate dehydrogenase deficiency; congenital hereditary defects in haemoglobin synthesis; and deficits in other nutrients, e.g. vitamins A, B₁₂, and C, and folic acid.

Blood loss such as that associated with schistosomiasis, hookworm infestation, haemorrhage in childbirth, and trauma, can also result in both iron deficiency and anaemia. Lastly, as with vitamin A deficiency, inhibition of the normal metabolism of iron can result in anaemia. These causes of anaemia are not addressed in detail in this guidebook.

The relationship between anaemia and iron deficiency in a population is illustrated in Figure 1 on the opposite page (5). In particular, it is noted that the extent of the overlap between iron deficiency and iron deficiency anaemia varies considerably from one population to another and according to gender and age groups.

The degree of overlap between rates of total anaemia and of iron deficiency anaemia also varies with the population observed. The greatest overlap occurs in populations in which dietary iron absorbability is low or blood loss is common due to hookworm infestation.
Figure 1. Conceptual diagram of the relationship between iron deficiency and anaemia in a hypothetical population

The pallor of anaemia was associated with weakness and tiredness long before its cause was known. Now it is recognized that even without anaemia, mild to moderate iron deficiency has adverse functional consequences (6).

Iron deficiency adversely affects

- the cognitive performance, behaviour, and physical growth of infants, preschool and school-aged children;
- the immune status and morbidity from infections of all age groups; and
- the use of energy sources by muscles and thus the physical capacity and work performance of adolescents and adults of all age groups.

Specifically, iron deficiency anaemia during pregnancy

- increases perinatal risks for mothers and neonates; and
- increases overall infant mortality.

Moreover, iron-deficient animals and humans have impaired gastrointestinal functions and altered patterns of hormone production and metabolism. The latter include those for neurotransmitters and thyroidal hormones which are associated with neurological, muscular, and temperature-regulatory alterations that limit the capacity of individuals exposed to the cold to maintain their body temperature. In addition, DNA replication and repair involve iron-dependent enzymes.

### 3.1 Cognitive development

In experimental animals, iron has been shown to play a key role in brain function. Several areas of the brain contain iron, sometimes in large quantities. Iron-deficient animals show alterations both in neurotransmitters and behaviour that do not usually respond to iron replenishment.
IRON DEFICIENCY ANAEMIA

There is strong evidence that findings from animal studies also apply to humans. For example, iron deficiency anaemia has been conclusively seen to delay psychomotor development and impair cognitive performance of infants in Chile (7), Costa Rica (8), Guatemala (9), and Indonesia (10); of preschool and school-aged children in Egypt (11), India (12), Indonesia (13,14), Thailand (15), and the USA (16,17).

Adolescent girls whose diet was supplemented with iron felt less fatigued; their ability to concentrate in school increased and their mood improved (18). Neurological malfunction in young children, adolescents, and adults - as determined by electrophysiological measurements - has also been documented as being associated with iron deficiency (19).

In Costa Rica, children who had moderate anaemia as infants achieved lower scores on intelligence (IQ) tests and other cognitive performance upon entry in school than did children who were non-anaemic during infancy. This finding emerged even when the tests were controlled for a comprehensive set of socioeconomic factors (11). This result was recently confirmed in Chile (20). On the other hand, in Thailand the poor performance in Thai language and mathematics tests of children with low haemoglobin levels was not reversed by iron supplementation (15).

Thus, iron deficiency can impair cognitive performance at all stages of life. Moreover, the effects of iron deficiency anaemia in infancy and early childhood are not likely to be corrected by subsequent iron therapy. An estimated 10-20% of preschool children in developed countries, and an estimated 30-80% in developing countries, are anaemic at 1 year of age (21). These children will have delayed psychomotor development, and when they reach school age they will have impaired performance in tests of language skills, motor skills, and coordination, equivalent to a 5 to 10 point deficit in IQ.

3.2 Resistance to infection

Morbidity from infectious disease is increased in iron-deficient populations (22-26), because of the adverse effect of iron deficiency on the immune system (27-30). In these situations, leukocytes have a reduced capacity to kill ingested microorganisms (31-34) and lymphocytes a decreased ability to replicate when stimulated by a mitogen. Also in such cases, there occurs a lowered concentration of cells responsible for cell-mediated immunity (31, 35-37) and a depressed skin-test response to common antigens (31,35). Iron supplementation and milk or cereal fortification among deficient children has been reported to reduce morbidity from infectious disease (38).
3.3 Work capacity and productivity

A linear relationship has been reported between iron deficiency and work capacity for agricultural workers in Colombia (39), Guatemala (40), Indonesia (41), Kenya (42,43), and Sri Lanka (44-46). Work capacity returned rapidly to normal with iron supplementation. Similarly, iron supplementation increased work output among road workers and rubber tappers in Indonesia (24); tea pickers in Indonesia (26,41) and Sri Lanka (44-46); agricultural workers in India (47), Guatemala (40), and Colombia (39); and industrial workers in Kenya (48), China (49), and other countries. Gains in productivity and take-home pay ranged from 10% to 30% of previous levels.

Compared with non-anaemic women, anaemic female workers in China were 15% less efficient in performing their work. They spent 6% less energy on their out-of-work activities, had 4% lower maximal work capacity, and had 12% lower overall productivity, as compared to levels achieved after anaemia was corrected by iron treatment for 4 months (49). Similarly, non-anaemic iron-deficient adolescent female runners significantly improved their levels of endurance and physical performance after supplementation with iron, as compared with those of a placebo control group (50).

3.4 Pregnancy

Iron deficiency in childbearing women increases maternal mortality (51), prenatal and perinatal infant loss, and prematurity (52,53). Forty percent of all maternal perinatal deaths are linked to anaemia. Favourable pregnancy outcomes occur 30-45% less often in anaemic mothers, and their infants have less than one-half of normal iron reserves (54).

Such infants require more iron than is supplied by breast milk, at an earlier age, than do infants of normal birth weight (55). Moreover, if pregnancy-induced iron deficiency is not corrected, women and their infants suffer all the consequences described above.

3.5 Growth

Growth improved in iron-deficient children who were given supplementary iron in Indonesia (56), Kenya (57), and Bangladesh (58), as well as in the United Kingdom (59) and the United States (60). Whether or not an effect of iron supplementation is observed apparently depends on local factors. These include frequency of diarrhoea and other infections, age at iron depletion, and other dietary factors.
3.6 Endocrine and neurotransmitters

Iron deficiency alters the production of triiodothyronine (T₃) and thyroid function in general, and the production and metabolism of catecholamines and other neurotransmitters. This results in impaired temperature response to a cold environment.

In both experimental animals and human subjects, those with iron deficiency anaemia more readily become hypothermic and have a depressed thyroid function (61-65). This condition may be the cause of some of the discomfort from cold felt by poorly nourished individuals at temperatures in which well-nourished persons are quite comfortable.

3.7 Heavy-metal absorption

An important consequence of iron deficiency is an apparent increased risk of heavy-metal poisoning in children. Iron-deficient individuals have an increased absorption capacity that is not specific to iron. Absorption of other divalent heavy metals, including toxic metals such as lead and cadmium, is also increased (66).

Prevention of iron deficiency, therefore, reduces the number of children susceptible to lead poisoning. Such prevention may also help to reduce their lead burden after exposure to high levels of lead from chipped lead paints, pollution from automobile fumes (such as occurs in many cities), or other excessive exposure to lead in the environment (67).
National socioeconomic development, as well as personal health and self-fulfilment, are impaired by iron deficiency. The negative impact on national development can be estimated from:

- the number of individuals affected in various age and gender categories;
- the severity of the deficiency; and
- the duration and consequences of the condition.

The economic implications of such conditions include:

- the costs incurred by the public and private sectors in therapeutic measures for the prevalent level of anaemia;
- the societal consequences of increased maternal mortality and resultant restraints on productivity; and
- the long-term projected negative consequences of impaired mental development on human capital formation.

The estimation of disability adjusted life years (DALYs) is an expression of years of life lost (YLL) and years lived with disability (YLD). DALYs provide an overall view of the magnitude of economic losses to a population (68).

Other indirect social and health consequences of impaired health and vitality are difficult to estimate and are often not considered. For example, among resource-poor societies the premature death of a mother and the lower income-generating capacity of iron-deficient and anaemic workers translates into greater rates of disease and overall undernutrition.
This vicious circle impairs individual, family, and community, as well as overall socioeconomic development. Consequently, estimates of only the economic cost of iron deficiency are conservative understatements of the true handicap imposed on society.

Costs of interventions specifically directed at nutrition and health education, dietary diversification, and other public health interventions that also result in improvements in iron nutrition, are not considered here. Data are lacking to allow even a rough approximation of the effectiveness of these measures for controlling iron deficiency. However, the general consensus is that if these interventions are competently carried out, they are highly cost-effective and sustainable.

There is a general scarcity of information both on the actual cost of programmes for the control of iron deficiency, and on the benefits obtained by its correction. Various programme budgetary considerations include the costs of:

- iron compounds required to treat anaemia and control iron deficiency;
- provision of iron fortification programmes;
- facilities, personnel time, logistics support; and
- programme monitoring and evaluation.

Iron compounds are no more than 7% of the total cost of supplementation programmes. In the case of iron fortification, the proportion of the cost of the most expensive iron compound may reach 27% of the total cost of the product because of the much lower cost of the other components. Generally, ongoing expenditures incurred in the treatment of anaemic subjects, and those involved in purchasing pharmaceutical preparations containing iron, are ignored, even though these may be significant.

The percentage efficiency of each intervention to control iron deficiency should also be considered when developing cost-benefit estimates. For example, successfully implemented iron supplementation programmes are considered to be at least 70% effective in the short term. As another example, general iron fortification programmes are considered to be 93% effective in the long term.
Estimates of benefits are made on the basis of projections from the correction of deficits caused by iron deficiency. These projections include lives saved; incomes increased; and deficits prevented in mental performance at all ages, including learning capacity at school. Resultant savings in treatment costs when iron deficiency is prevented should also be considered when calculating benefits to society.

Once both costs and benefits of various programmes have been estimated, the cost-benefit ratio of interventions can be derived. Several attempts have been made to develop models for comparative purposes among interventions (69,70), as applied to an ‘average’ developing world population. These models involve prevalence of iron deficiency by age group, using neither the lower nor the higher costs of the various intervention components.

Estimates of fixed costs, e.g. depreciation and maintenance of health-post buildings and vehicles, monitoring, and costs of health-post personnel, are estimated on the assumption that programmes to control iron deficiency share these costs with three other programmes: family planning, antenatal care, and maternal-infant care. Accordingly, each programme incurs only one-quarter of the total estimated fixed costs.

When programmes are primarily community-based, costs are estimated to be further reduced by three-quarters. The ‘average’ fortification programme will include the cost of the most expensive compound, iron-EDTA (sodium iron ethylenediaminetetraacetic acid).

Table 1 on the following page presents estimates of the relative effectiveness and cost of various strategies, in terms of DALYs gained by each, and the cost per DALY.
Table 1. Relative effectiveness and cost per Disability Adjusted Life Year (DALY) of various prevention strategies

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Number of DALYs gained</th>
<th>Cost per DALY Per day</th>
<th>Cost per DALY Per week</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Short-term</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Benefits or costs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prenatal supplementation</td>
<td>511</td>
<td>100</td>
<td>51</td>
</tr>
<tr>
<td>Widespread supplementation</td>
<td>4665</td>
<td>88</td>
<td>24</td>
</tr>
<tr>
<td>Universal fortification plus prenatal supplementation</td>
<td>5038</td>
<td>16</td>
<td>11</td>
</tr>
<tr>
<td>Universal fortification plus residual supplementation</td>
<td>5394</td>
<td>39</td>
<td>16</td>
</tr>
<tr>
<td><strong>Long-term</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Human capital formation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supplementation</td>
<td>2679</td>
<td>37</td>
<td>17</td>
</tr>
<tr>
<td>Fortification</td>
<td>3332</td>
<td>9</td>
<td>-</td>
</tr>
</tbody>
</table>

Source: Murray & Lopez (68).
5.1 Prevalence

Iron deficiency is the most common and widespread nutritional disorder in the world (71). As well as affecting a large number of children and women in non-industrialized countries, it is the only nutrient deficiency which is also significantly prevalent in virtually all industrialized nations. There are no current global figures for iron deficiency, but using anaemia as an indirect indicator it can be estimated that most preschool children and pregnant women in non-industrialized countries, and at least 30-40% in industrialized countries, are iron deficient (21, 51).

Nearly half of the pregnant women in the world are estimated to be anaemic: 52% in non-industrialized - as compared with 23% in industrialized - countries (see Table 2a, below, and 2b, following page). In industrialized countries, however, most pregnant women are thought to suffer from some degree of iron deficiency. For example, 75% of pregnant women attending universities in Paris showed evidence of depleted iron stores (72).

Table 2a. Estimated percentages of anaemia prevalence (1990-95) based on blood haemoglobin concentration (21, 51)

<table>
<thead>
<tr>
<th>Percentage of total affected population in:</th>
<th>Industrialized countries</th>
<th>Non-industrialized countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children (0-4 years)</td>
<td>20.1</td>
<td>39.0</td>
</tr>
<tr>
<td>Children (5-14 years)</td>
<td>5.9</td>
<td>48.1</td>
</tr>
<tr>
<td>Pregnant women</td>
<td>22.7</td>
<td>52.0</td>
</tr>
<tr>
<td>All women (15-59 years)</td>
<td>10.3</td>
<td>42.3</td>
</tr>
<tr>
<td>Men (15-59 years)</td>
<td>4.3</td>
<td>30.0</td>
</tr>
<tr>
<td>Elderly (+60 years)</td>
<td>12.0</td>
<td>45.2</td>
</tr>
</tbody>
</table>
Table 2b. *Estimated prevalence of anaemia (1990-1995) by WHO Region based on blood haemoglobin concentration (21,51)*

<table>
<thead>
<tr>
<th>WHO Regions</th>
<th>Total affected population, <em>in thousands</em></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Children (0-4 years)</td>
</tr>
<tr>
<td>Africa</td>
<td>45 228</td>
</tr>
<tr>
<td>Americas</td>
<td>14 200</td>
</tr>
<tr>
<td>South-East Asia</td>
<td>111 426</td>
</tr>
<tr>
<td>Europe</td>
<td>12 475</td>
</tr>
<tr>
<td>Eastern Mediterranean</td>
<td>33 264</td>
</tr>
<tr>
<td>Western Pacific</td>
<td>29 793</td>
</tr>
<tr>
<td>Overall</td>
<td>245 386</td>
</tr>
</tbody>
</table>
Anaemia is particularly prominent in south Asia. In India, for example, up to 88% of pregnant and 74% of non-pregnant women are affected. Throughout Africa, about 50% of pregnant and 40% of non-pregnant women are anaemic. West Africa is the most affected, and southern Africa the least. In Latin America and the Caribbean, prevalences of anaemia in pregnant and non-pregnant women are about 40% and 30% respectively. The highest levels are in the Caribbean, reaching 60% in pregnant women on some islands (51, 21).

Prevalence data for various age groups are not available for all countries. However, the prevalence rate among preschool children is usually similar to, or higher than, the rate among pregnant women. Epidemiological mapping of prevalence requires cut-off levels, or criteria for grading the public health severity of anaemia. Table 3 provides a provisional schema for this purpose.

In most industrialized countries, the prevalence of anaemia among pregnant women is around 20%. It is therefore considered reasonable to classify these populations as having a medium prevalence, since a prevalence of up to 5% may not necessarily be regarded as abnormal in any population.

Table 3. Proposed classification of public health significance of anaemia in populations on the basis of prevalence estimated from blood levels of haemoglobin or haematocrit

<table>
<thead>
<tr>
<th>Category of public health significance</th>
<th>Prevalence of anaemia (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe</td>
<td>&gt; or = 40</td>
</tr>
<tr>
<td>Moderate</td>
<td>20.0 – 39.9</td>
</tr>
<tr>
<td>Mild</td>
<td>5.0 – 19.9</td>
</tr>
<tr>
<td>Normal</td>
<td>&lt; or = 4.9</td>
</tr>
</tbody>
</table>

*a Based on cut-off levels of haemoglobin and haematocrit given in Table 6.

5.2 Epidemiology

The prevalence of iron deficiency varies greatly according to host factors: age, gender, physiological, pathological, environmental, and socioeconomic conditions. Iron requirements and recommended iron intakes are summarized in Table 4, and the factors that influence them are discussed beginning on page 20.
### Table 4. Iron requirements and recommended iron intakes by age and gender group

<table>
<thead>
<tr>
<th>Groups</th>
<th>Age (years)</th>
<th>Mean body weight (kg)</th>
<th>Required iron intake for growth (mg/day)</th>
<th>Median iron losses (mg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Basal</td>
</tr>
<tr>
<td>Children</td>
<td>0.5-1</td>
<td>9.0</td>
<td>0.55</td>
<td>0.17</td>
</tr>
<tr>
<td></td>
<td>1-3</td>
<td>13.3</td>
<td>0.27</td>
<td>0.19</td>
</tr>
<tr>
<td></td>
<td>4-6</td>
<td>19.2</td>
<td>0.23</td>
<td>0.27</td>
</tr>
<tr>
<td></td>
<td>7-10</td>
<td>28.1</td>
<td>0.32</td>
<td>0.39</td>
</tr>
<tr>
<td>Males</td>
<td>11-14</td>
<td>45.0</td>
<td>0.55</td>
<td>0.62</td>
</tr>
<tr>
<td></td>
<td>15-17</td>
<td>64.4</td>
<td>0.60</td>
<td>0.90</td>
</tr>
<tr>
<td></td>
<td>18+</td>
<td>75.0</td>
<td></td>
<td>1.05</td>
</tr>
<tr>
<td>Females</td>
<td>11-14(^b)</td>
<td>46.1</td>
<td>0.55</td>
<td>0.65</td>
</tr>
<tr>
<td></td>
<td>11-14</td>
<td>46.1</td>
<td>0.55</td>
<td>0.65</td>
</tr>
<tr>
<td></td>
<td>15-17</td>
<td>56.4</td>
<td>0.35</td>
<td>0.79</td>
</tr>
<tr>
<td></td>
<td>18+</td>
<td>62.0</td>
<td></td>
<td>0.87</td>
</tr>
<tr>
<td>Post menopause</td>
<td></td>
<td>62.0</td>
<td></td>
<td>0.87</td>
</tr>
<tr>
<td>Lactating</td>
<td></td>
<td>62.0</td>
<td></td>
<td>1.15</td>
</tr>
</tbody>
</table>

\(^a\) Total absolute requirements include requirement for growth, basal losses and, in female, menstrual losses.

\(^b\) Non-menstruating.

\(^c\) Bioavailability of dietary iron during this period varies greatly.
Table 4 (continued). Iron requirements and recommended iron intakes by age and gender group

<table>
<thead>
<tr>
<th>Total absolute requirements(^a) (median) (mg/day)</th>
<th>Recommended iron intakes to cover requirements of 97.5% of populations for diets of different bioavailability (mean +2 SD) (mg/day)</th>
<th>Level of dietary iron bioavailability %</th>
</tr>
</thead>
<tbody>
<tr>
<td>High 15%</td>
<td>Intermediate 12%</td>
<td>Low 10%</td>
</tr>
<tr>
<td>0.72</td>
<td>6.2(^c)</td>
<td>9.3(^c)</td>
</tr>
<tr>
<td>0.46</td>
<td>3.9</td>
<td>5.8</td>
</tr>
<tr>
<td>0.50</td>
<td>4.2</td>
<td>6.3</td>
</tr>
<tr>
<td>0.71</td>
<td>5.9</td>
<td>8.9</td>
</tr>
<tr>
<td>1.17</td>
<td>9.7</td>
<td>14.6</td>
</tr>
<tr>
<td>1.50</td>
<td>12.5</td>
<td>18.8</td>
</tr>
<tr>
<td>1.05</td>
<td>9.1</td>
<td>13.7</td>
</tr>
<tr>
<td>1.20</td>
<td>9.3</td>
<td>14.0</td>
</tr>
<tr>
<td>1.68</td>
<td>21.8</td>
<td>32.7</td>
</tr>
<tr>
<td>1.62</td>
<td>20.7</td>
<td>31.0</td>
</tr>
<tr>
<td>1.46</td>
<td>19.6</td>
<td>29.4</td>
</tr>
<tr>
<td>0.87</td>
<td>7.5</td>
<td>11.3</td>
</tr>
<tr>
<td>1.15</td>
<td>10.0</td>
<td>15.0</td>
</tr>
</tbody>
</table>

Adapted from: Vitamin and mineral requirements in human nutrition, FAO/WHO (to be published)

Source: References (4,73).
5.2.1 Age

Full-term infants are normally born with adequate iron stores in the liver and haematopoietic tissue, because of destruction of fetal red blood cells soon after birth. This leads to deposition of iron in these tissues, especially if the cord is ligated after it stops pulsating.

Breast milk is relatively low in iron, although the iron in breast milk is much better absorbed than that in cows’ milk. Iron deficiency commonly develops after six months of age if complementary foods do not provide sufficient absorbable iron, even for exclusively breastfed infants.

Iron requirements on a body weight basis are proportional to growth velocity. Accordingly, in addition to women in their reproductive years as a result of physiological losses, iron deficiency is most common in the preschool years and during puberty. Another peak may occur in old age, when diets frequently deteriorate in quality and quantity.

5.2.2 Gender

Following menarche, adolescent females often do not consume sufficient iron to offset menstrual losses. As a result, a peak in the prevalence of iron deficiency frequently occurs among females during adolescence.

5.2.3 Physiological state

Substantial amounts of iron are deposited in the placenta and fetus during pregnancy. This results in an increased need of about 700-850 mg in body iron over the whole pregnancy.

Overall, iron absorption is increased during pregnancy, when menstruations stop. Pregnant women still do not absorb sufficient additional iron, however, and the risk of iron deficiency increases.

Lactation results in loss of iron via breast milk. Consequently, for some women a deficiency developed during pregnancy may be perpetuated during lactation. In terms of iron balance, however, lactational amenorrhea more than compensates for iron lost through breast milk.
5.2.4 Pathological state

Common infections, especially those which are chronic and recurrent, may impair haematopoiesis and consequently cause anaemia. Malaria by haemolysis and some parasitic infections, e.g. hookworm, trichuriasis, amoebiasis, and schistosomiasis (both vesical and intestinal forms), cause blood loss directly. This blood loss contributes to iron deficiency.

Other important causes of anaemia include genetic factors, e.g. thalassemia, sickle cell trait, and glucose-6-phosphate dehydrogenase deficiency (G6PD). Because these genetic factors are not due to iron deficiency, they are not discussed in this guidebook.

These other causes of anaemia are mentioned, however, as a reminder that they should be considered when choosing and focusing on population groups for assessment and surveillance purposes. In this way, more appropriate interventions can be developed.

It should also be noted that these genetic conditions, except for thalassemia major - which is rare - do not prevent the development of iron deficiency, and may coincide with it.

5.2.5 Environmental factors

A given diet may be low in iron or may contain adequate amounts of iron which are of low bioavailability (see Chapter 8). Other nutrients necessary for haematopoiesis may also be deficient. These include folic acid, vitamins A, B₁₂, and C, protein, and copper and other minerals (73).

Trauma or childbirth can result in acute or chronic blood loss, with consequent iron deficiency and anaemia

5.2.6 Socioeconomic status

Iron deficiency is most common among groups of low socioeconomic status.
6.1 Individual and population-based assessment

Surveillance of iron deficiency involves an ongoing process of recording and assessing iron status in an individual or a community. Worldwide, the most common method of screening individuals or populations for iron deficiency involves determining the prevalence of anaemia by measuring blood haemoglobin or haematocrit levels.

A major limitation of each of these two tests, however, lies in the fact that anaemia is not a specific indication of iron deficiency. As noted in Chapter 5, other nutrient deficiencies and most infectious diseases can also result in significant anaemia.

One common practice in assessing whether or not anaemia is due to iron deficiency involves monitoring the response in haemoglobin or haematocrit levels after 1 or 2 months of oral supplementation with iron. An increase of 10 g/l in haemoglobin or 3% in haematocrit is indicative of iron deficiency. Individual management in resource-poor countries is likely to be based mainly upon either haemoglobin or haematocrit assessment - or both - and upon their response to initial iron therapy.

Another limitation of haemoglobin or haematocrit measurements is that levels change only when they are very low at the outset, and when iron deficiency is already severe. In resource-adequate situations, the usual practice involves the use of further, specific, and more sensitive tests for individual assessment. These include serum ferritin, transferrin saturation, and others.

This guidebook, however, deals primarily with population-based assessments. It does not elaborate on the selection, specificity, and sensitivity of various tests for individual assessment.
6.2 Purposes of biological assessments

Biological assessments are made to:

- Determine the magnitude, severity, and distribution of iron deficiency and anaemia, and preferably its main causes. This information can serve as a basis for planning policies and interventions, and as a baseline against which to assess their impact.

- Identify populations more affected or at greater risk. This information enables national authorities to select priority areas for action, especially if resources are limited.

- Monitor trends in prevalence and evaluate the impact of interventions. Other programme indicators are also needed for monitoring programme implementation.

- Measure progress towards achieving the goals adopted by the International Community.

- Provide the basis for advocacy programmes for iron deficiency and anaemia prevention in affected and vulnerable populations.

The approaches used in surveillance range from the routine collection and analysis of indicators in health centres (especially antenatal clinics) and analysis of laboratory records, to periodic special community-based assessments and the integration of iron status or anaemia assessment in other population-based surveys.

Clinic-based data are generally not representative of an entire population. However, periodic assessments using the same methods in the same service context may enable trends to be effectively followed. Any assessment should include an analysis of factors causing or contributing to anaemia, in addition to iron deficiency.
6.3 Selection of subjects for assessment

6.3.1 Vulnerability

Vulnerability to iron deficiency varies greatly with each stage of the life cycle. This variation is due to changes in iron stores, level of intake, and needs relating to growth or iron losses. In general, children aged 6 months through 5 years of age (74) and women of childbearing age (75) - especially during pregnancy - are the most vulnerable groups.

Unless born preterm or with low birth weight, most infants are at low risk before 6 months of age because their iron stores are usually still adequate from the perinatal period. Accordingly, the earliest age to begin assessment of iron status is normally between 6 and 9 months; assessment may begin earlier (e.g. from 4 months) in communities with low iron status.

Among children under 5 years of age, the greatest prevalence of iron deficiency occurs during the second year of life, due to low iron content in the diet and rapid growth during the first year. In areas with a high prevalence of hookworm infestation, school-aged children as well as adults can also develop significant iron deficiency (76).

6.3.2 Accessibility

For monitoring purposes, infants and pregnant women are the most accessible groups because they frequently attend primary health care and maternal and child health clinics where assessments can be conducted. Non-pregnant women can sometimes be monitored through family planning services. School-aged children can be reached through school health services. Preschool children and adult men are the least accessible groups because they have no regular contact with the health care system.

6.3.3 Representativeness

For survey or surveillance purposes, the sampled population should be representative of those populations targeted for a universal or specific intervention programme. Although there are significant variations in iron status and prevalence of anaemia across age groups and strata, iron status across communities with similar dietary patterns tends to be comparable among those of the same socioeconomic status. Traditionally-designed nutritional surveys based on 30 to 60 clusters are adequate for assessing iron status.
Prevalence rates for one subgroup (by age or gender) cannot be used as a proxy for the rest of the population because risks of iron deficiency vary widely. In most developing countries, the prevalence of iron deficiency is high for both infants and women of childbearing age because of low iron intake relative to increased iron requirements.

In industrialized countries, however, infants are relatively more affected. Occasionally there are populations in which infants and preschool children have high rates of iron deficiency anaemia even though the rate is low among adult women (77). Dietary patterns of infants, preschool children, and adults in such situations are very different. Hence, high iron intake among adults offers no assurance of adequate iron in the diets of infants or preschool children.

In most settings where malaria, hookworm, or schistosomiasis are not significant contributors to anaemia in adults, high prevalence rates of iron deficiency anaemia are usually only found in women of childbearing age. Adult men who are free of diseases associated with blood loss are not appreciably affected by relatively low iron intake; they have lower normal iron requirements to compensate for iron losses (78).

6.4 General issues in defining iron status indicators

Even though there may be many causes of anaemia, dietary iron deficiency is usually either the main or a major contributing factor. Other significant nutritional deficiencies (e.g. low intakes of folic acid and vitamins A, B₁₂, and C) and infectious diseases (e.g. malaria and hookworm) may also contribute to anaemia.

Iron deficiency anaemia reflects the severe end of the spectrum of depletion. Where rates greater than 30-40% occur in a defined age-gender group, most non-anaemic individuals in that group will be sufficiently iron-deficient to be at risk of adverse functional consequences (78). In these situations, even without specific assessment or in the presence of other factors contributing to anaemia, the institution of a broad spectrum of interventions to improve the iron nutrition of vulnerable sub-populations is justified.

Several well-established laboratory indices for assessing and monitoring iron status are available. Of these, however, only haemoglobin or haematocrit tests can be routinely performed in field settings. More precise, multiple biochemical tests of iron status can only be conducted in resource-adequate countries or under special research or survey conditions (79).
The usefulness and limitations of using anaemia as a surrogate for iron status has been established by studies which have concurrently assessed iron status and performed other available iron-related tests. These other tests include mean corpuscular volume, mean corpuscular haemoglobin, serum ferritin, transferrin saturation, erythrocyte protoporphyrin, and (more recently) transferrin receptors.

6.5 The spectrum of iron nutritional status

In normal individuals, the iron used for haemoglobin formation accounts for about two-thirds of total body iron. In men, about one-third of body iron may be deposited as haemosiderin or ferritin in stores that can be mobilized when there occurs a need to supply iron in a functionally active form.

About 14% of iron is used for other vital physiological functions (80). In addition, a small pool of iron in plasma is in transit, and bound to the iron carrier transferrin (81).

Measurements of haemoglobin, serum ferritin, serum iron, and transferrin (total iron-binding capacity) enable iron status to be characterized in detail (82). However, each of these determinations has well-recognized limitations under field conditions, i.e. single or combined measurements of iron status show that response to therapeutic trials is greater than expected.

As previously noted, iron deficiency anaemia represents the extreme low end of the spectrum of iron status. The severity of anaemia is differentiated by the severity of the reduction in haemoglobin level.

The term “anaemia” is sometimes used synonymously with “iron deficiency anaemia”. Clearly, however, these terms do not cover the same reality. There are about 2-5 times more iron-deficient than iron-deficient-anaemic individuals. There are also many causes of anaemia besides iron deficiency, particularly in tropical regions.

In any case, however, iron deficiency is the predominant nutritional deficiency causing anaemia and is present even when other causes of anaemia are recognized. There are, however, mild-to-moderate forms of iron deficiency in which anaemia is absent.
Data collected in US national surveys revealed that 30-40% of children under 5 years of age, and women of childbearing age who had evidence of iron deficiency, were also anaemic (83). This relationship provides a basis for estimating the prevalence of iron deficiency - with or without anaemia - by using the prevalence of iron deficiency anaemia.

Assuming that this relationship is valid for other populations with a higher prevalence of iron deficiency, some degree of iron deficiency would be present in about 50% of the population of these age and gender groups if anaemia prevalence exceeds 20%, and in virtually the entire population of the same age and gender groups if anaemia prevalence exceeds 40% (Figure 2).

In addition, the relative proportion of anaemia due to iron deficiency increases as the prevalence of anaemia increases. Up to a prevalence of iron deficiency anaemia of 40%, the prevalence of iron deficiency will be about 2.5 times that of anaemia.

**Figure 2. Projected prevalence of iron deficiency based on prevalence of iron deficiency anaemia**

*Source: Yip R, based on the second US National Health and Nutrition Survey (NHANES II), and Pizarro et al. (84).*
The hypothetical relationship noted above does not apply to prevalence rates for overall anaemia. Anaemia from other causes must be excluded before the proportion of the population that is iron-deficient can be derived from Figure 2.

The programmatic implications of this projection are as follows. When the prevalence of iron deficiency anaemia reaches the 20-30% level in the age-gender group under evaluation, it may be more effective - and possibly more efficient - to provide universal supplementation to that entire group than to screen for individual case-management purposes.

A decision analysis using the US national survey data reached a similar conclusion (85). The same analysis also concluded that screening becomes ineffective by the time the prevalence of anaemia is lower than 5%, because most of the cases are not related to iron deficiency.

Screening for programmatic purposes should therefore be considered for anaemia prevalences between 5% and 20%. A prevalence within this range suggests appropriate interventions based on dietary modifications, provision of iron-fortified foods, targeted iron supplementation, and control of infections.

6.6 Application of iron-related indicators to specific settings

Variations in the prevalence of iron deficiency worldwide, the availability of laboratories for testing, and the occurrence of factors other than iron deficiency that cause anaemia, require that iron-related indicators be divided into three categories. These categories of indicators are applied in settings considered to be resource-poor, resource-intermediate, or resource-adequate. Resource-adequate settings correspond to the commonly-used term “developed country”, while the other two settings are usually classified as situations which are typical of “less developed” countries.

The reason for this differentiation lies in the wide variation of resources among and within “less developed” countries. For example, the towns and cities may be resource-intermediate while the rural areas more resource-poor.

Table 5 summarizes which iron status indicators to apply, according to resource availability. It is also assumed that the three levels of resources, i.e. poor, intermediate, and adequate, roughly correspond to the three degrees of severity of anaemia: severe, moderate, and mild.
<table>
<thead>
<tr>
<th>Resource conditions&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Poor</th>
<th>Intermediate</th>
<th>Adequate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prevalence of anaemia</strong></td>
<td>Severe</td>
<td>Moderate</td>
<td>Mild</td>
</tr>
<tr>
<td><strong>Clinical decisions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Screening</strong></td>
<td>Clinical examination&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Haemoglobin or haematocrit for screening</td>
<td>Haemoglobin or haematocrit for screening</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Additional tests&lt;sup&gt;c&lt;/sup&gt;:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Serum ferritin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Transferrin saturation</td>
</tr>
<tr>
<td><strong>Confirmation or diagnostic</strong></td>
<td>Haemoglobin or haematocrit</td>
<td>Haemoglobin or haematocrit response to iron administration</td>
<td>Haemoglobin or haematocrit response to iron administration</td>
</tr>
<tr>
<td></td>
<td>Clinical response to iron administration</td>
<td>Serum ferritin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Erythrocyte protoporphyrine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Transferrin saturation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Transferrin receptor</td>
<td></td>
</tr>
<tr>
<td><strong>Public health and population-based decisions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Special assessment or survey</strong></td>
<td>Haemoglobin or haematocrit</td>
<td>Haemoglobin or haematocrit</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Optional: Mean cell volume</td>
<td>Serum ferritin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Transferrin saturation</td>
<td>Erythrocyte protoporphyrine&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Transferrin receptor</td>
<td></td>
</tr>
<tr>
<td><strong>Diagnosis of causes of anaemia</strong></td>
<td>Response to iron supplement&lt;sup&gt;e,f&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Long-term surveillance</strong></td>
<td>Haemoglobin or haematocrit from PHC or MCH centres</td>
<td>Haemoglobin or haematocrit from PHC or MCH centres at selected sites</td>
<td>Haemoglobin or haematocrit from clinics&lt;sup&gt;g&lt;/sup&gt;</td>
</tr>
</tbody>
</table>
Footnotes to Table 5 (opposite)

a Relative terms that correspond approximately to the level of development according to UN Classification (United Nations Development Programme. Human Development Report. New York, Oxford University Press, 1999).

b Severe prevalence of anaemia (> 40%) justifies universal iron supplementation without screening individuals. The clinical assessment of anaemia lacks sensitivity and, therefore, a prevalence of 2%-3% of cases clinically detected represents a severe problem.

c Serum ferritin or transferrin saturation in addition to haemoglobin or haematocrit is of interest in individuals for detecting mild forms of iron deficiency or iron overload.

d Specific iron biochemistry tests may lose some sensitivity in populations that also have high rates of infections.

e Anaemia response to treatment for malaria or hookworm should be considered in areas with a known incidence of these conditions.

f Where nutritional deficiencies, such as of folic acid, vitamin C, or vitamin A, are believed to contribute to anaemia, multiple supplementation should be considered.

g Consistent use of the same procedures, (e.g. compilation of data from clinics, even if inadequate for statistical assessment) may nevertheless reveal trends useful for population surveillance.
7.1 Assessment of anaemia

7.1.1 Criteria of anaemia

It is well known that normal haemoglobin distributions vary with age and gender, at different stages of pregnancy, and with altitude and smoking (86,87). There is also evidence of a genetic influence. In the United States, for example, individuals of African extraction have haemoglobin values 5 to 10 g/l lower than do those of European origin. This contrast is not related to iron deficiency (88).

The correct interpretation of haemoglobin or haematocrit values, therefore, requires the consideration of modulating factors in selecting appropriate cut-off values. Those values at sea level for haemoglobin and haematocrit corresponding to anaemia, are presented in Table 6. Table A3 in Annex 3 reflects haemoglobin and haematocrit levels at various altitudes.

Table 6. Haemoglobin and haematocrit levels below which anaemia is present in a population

<table>
<thead>
<tr>
<th>Age or gender group</th>
<th>Haemoglobin g/l</th>
<th>Haematocrit mmol/l</th>
<th>Haematocrit l/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children 6 months to 59 months</td>
<td>110</td>
<td>6.83</td>
<td>0.33</td>
</tr>
<tr>
<td>Children 5–11 years</td>
<td>115</td>
<td>7.13</td>
<td>0.34</td>
</tr>
<tr>
<td>Children 12–14 years</td>
<td>120</td>
<td>7.45</td>
<td>0.36</td>
</tr>
<tr>
<td>Non-pregnant women (above 15 years of age)</td>
<td>120</td>
<td>7.45</td>
<td>0.36</td>
</tr>
<tr>
<td>Pregnant women</td>
<td>110</td>
<td>6.83</td>
<td>0.33</td>
</tr>
<tr>
<td>Men (above 15 years of age)</td>
<td>130</td>
<td>8.07</td>
<td>0.39</td>
</tr>
</tbody>
</table>

a Conventional conversion factors: 100 g haemoglobin = 6.2 mmol haemoglobin = 0.30 l/l haematocrit. Adapted from reference (89), by splitting the age group for children 5-14 years and applying a haemoglobin cut-off level for those 5-11 years which has been lowered by 5 g/l to reflect the findings in non-iron-deficient children in the USA (cf. Table A1 in Annex 3).
Severe anaemia in pregnancy is defined as haemoglobin <70 g/l and requires medical treatment. Very severe anaemia is defined as haemoglobin <40 g/l. Very severe anaemia in pregnant women is a medical emergency due to the risk of congestive heart failure; maternal death rates are greatly increased.

Annex 3 provides age-related criteria for normal haemoglobin and haematocrit levels developed by the Centers for Disease Control and Prevention in Atlanta, USA (79). Criteria for stages of pregnancy, and adjustment factors for altitude and smoking are also provided. For populations of African extraction, recent analysis indicates that achieving a similar screening performance (sensitivity and specificity) requires a haemoglobin criterion that is 10 g/l (0.62 mmol/l) lower than those shown in Table 6 (90,91).

7.1.2 Clinical examination to detect severe anaemia

Severe anaemia is a major risk factor associated with greatly increased morbidity and mortality for young children and pregnant women. Prompt recognition of the condition, and treatment and clinical follow-up of individuals, are crucial in avoiding complications such as high-output heart failure. Subjects with severe anaemia can usually be detected by clinical examination for significant pallor of the eyelids, tongue, nail beds, and palms.

For clinically detecting haemoglobin levels of 50-80 g/l during childhood, a sensitivity and specificity of 60%-70% is reported. For those <50 g/l, a sensitivity of 93% and a specificity of 57% is reported (92). Among Ethiopian refugee women in Somalia, a sensitivity of 53% and specificity of 91% are reported (78). In young children, palm pallor is preferred to eyelid pallor as a clinical diagnostic sign, due to the frequency of conjunctivitis which causes redness even in anaemic subjects.

In resource-poor settings where routine laboratory testing of haemoglobin or haematocrit is not feasible, clinical signs should be regularly used to screen individual women and children. The purpose of this screening should be to identify high-risk subjects before the onset of life-threatening complications.

Considering the increased risk of human immunodeficiency virus (HIV) transmission via blood transfusion, and the risk of short-term mortality from transfusion itself (93), clinical examination to identify and manage cases of severe anaemia may provide one strategy to reduce the need for transfusion. The use of clinical indicators is recommended for screening for treatment of subjects with severe anaemia, but it is not recommended for population-based surveys of anaemia.
7.1.3 Haemoglobin measurement

The prevalence of anaemia in a population is best determined by using a reliable method of measuring haemoglobin concentration (94). Compared with the cost and difficulty of biochemically assessing the prevalence of iodine deficiency and vitamin A deficiency, the determination of the prevalence of anaemia in a population is relatively simple and inexpensive.

The only methods generally recommended for use in surveys to determine the population prevalence of anaemia by haemoglobinometry are the cyanmethemoglobin method in the laboratory and the HemoCue system.

**The cyanmethemoglobin method** for determining haemoglobin concentration is the best laboratory method for the quantitative determination of haemoglobin. It serves as a reference for comparison and standardization of other methods (94).

A fixed quantity of blood is diluted with a reagent (Drabkins solution) and haemoglobin concentration is determined after a fixed time interval in an accurate, well-calibrated photometer.

**The HemoCue system** is a reliable quantitative method for determining haemoglobin concentrations in field surveys (95), based on the cyanmethemoglobin method. The HemoCue system consists of a portable, battery-operated photometer and a supply of treated disposable cuvettes in which blood is collected.

The system is uniquely suited to rapid field surveys because the one-step blood collection and haemoglobin determination do not require the addition of liquid reagents. Survey field staff without specialized laboratory training have been successfully trained to use this device.* This equipment can be obtained through UNICEF.

The HemoCue system gives satisfactory accuracy and precision when evaluated against standard laboratory methods (96). Long-term field experience has also shown the instrument to be stable and durable. These features make it possible to include haemoglobin determinations in multipurpose health and nutrition surveys.

* In 1998, the cost of the photometer was approximately US$320 and a supply of disposable cuvettes US$0.30 per test.
IRON DEFICIENCY ANAEMIA

There exists a range of other quantitative and semi-quantitative methods for determining haemoglobin concentration. A report of the strengths and weaknesses of the various methods that may have an application in clinical practice is available. Again, however, only the two methods described above are generally recommended.

7.1.4 Haematocrit or packed cell volume

Haematocrit or packed cell volume is a commonly performed clinical assessment frequently used in surveys of anaemia because of its simplicity and the widespread availability of the necessary equipment. Haematocrit measurement is an acceptable and recommended method for anaemia determination, but has no advantage compared to haemoglobin measurement. Moreover, reliable haematocrit determination requires a stable power supply.

For haematocrit determination, blood is collected in anticoagulant-treated capillary tubes and spun in a small, specially designed centrifuge. The volume of packed cells as a portion of the total volume of blood is measured and expressed as % whole blood.

Many referral hospitals have electronic cell counters. Provided that they are well calibrated and maintained, these devices can yield rapid and reliable indications of mean cell volume (MCV) and the number of red blood cells (RBC) from which a “calculated haematocrit” (MCV x RBC concentration) can be obtained. In general, centrifuge haematocrit and calculated haematocrit based on electronic counters are closely matched.

Although in most populations the prevalence of anaemia determined by using haematocrit or haemoglobin concentration (using the cut-off values given in Table 6), will be similar, results may not be identical. This difference in anaemia prevalence, obtained by using these two methods, may add to the complexity of a survey report and make the results more difficult for decision-makers to interpret. Accordingly, there is little advantage in determining haematocrit as well as haemoglobin during surveys.

A potential source of error in haemoglobin and haematocrit determination lies in inadequate technique in obtaining capillary blood. Care must be taken to ensure adequate puncture of the tissue and spontaneous blood flow from the wound. The key to accuracy is blood sampling from finger- or heel-prick (97).

7.2 Specific tests or procedures for assessing iron status

Iron status can be determined by several well-established tests in addition to measurement of haemoglobin or haematocrit. Unfortunately, however, there is no single standard test to assess iron deficiency without anaemia. The use of multiple tests only partially overcomes the limitation of a single test (79) and is not an option in resource-poor settings.

Moreover, iron-related tests do not all correlate closely with one another because each reflects a different aspect of iron metabolism (98). In anaemic individuals, such tests are used to confirm or help clarify the type or cause of anaemia.

Although these tests are utilized for special surveys in populations, they are not routinely conducted on a large scale because of their relatively high cost. This cost usually limits their use to settings with adequate resources. Even where feasible, most iron biochemical tests are of limited use in resource-poor settings. In such situations, other nutrient deficiencies and high rates of infections can interfere with the interpretation of such tests relative to iron status.

The following sections describe specific tests or procedures for assessing iron status.

7.2.1 Serum ferritin

The serum ferritin level is the most specific biochemical test that correlates with relative total body iron stores. A low serum ferritin level reflects depleted iron stores and hence is a precondition for iron deficiency in the absence of infection. Serum apoferritin is an acute-phase reactant protein and is therefore elevated in response to any infectious or inflammatory process. Consequently, serum ferritin in the normal range reflects only iron sufficiency in the absence of these conditions. Interpretation of serum ferritin levels is thus problematic in populations in which, with the exception of parasitic infections and malaria, the incidence of infection or inflammation is high.

Interpretation of serum ferritin as an indicator of the relative extent of depletion of iron stores is presented in Table 7 (following page). The generally accepted cut-off level for serum ferritin, below which iron stores are considered to be depleted, is <15 µg/l. Kits used for serum ferritin determination should be carefully calibrated against the WHO standard shown in Table 7.
Significant variations in serum ferritin levels relating to vulnerability to iron deficiency occur across age and gender groups. Infants, young children, and pregnant women usually have serum ferritin values near or in the range reflective of depletion; however, a low level *per se* does not imply functional iron deficiency. Only when the mobilizable iron supply for physiological function is inadequate is iron deficiency considered present.

Serum ferritin measurement is the preferred method for detecting depleted iron stores. However, it is of limited usefulness during pregnancy because it diminishes late in pregnancy, even when bone marrow iron is present.

### 7.2.2 Erythrocyte protoporphyrin

Levels of erythrocyte protoporphyrin, the precursor of haem, become elevated when the iron supply is inadequate for haem production. With adequate iron, erythrocyte protoporphyrin levels, like those of haemoglobin, are maintained within a well-defined normal range in healthy individuals. Table 8, on the following page, reflects the several equivalent units in which erythrocyte protoporphyrin cut-off levels can be expressed. In general, an elevated erythrocyte protoporphyrin level correlates well with low serum ferritin, and can serve to screen for moderate iron deficiency without anaemia (99).
Three commonly encountered conditions, in addition to iron deficiency, can cause a significant elevation of erythrocyte protoporphyrin: infection or inflammation, lead poisoning, and haemolytic anaemia. For this reason, the measurement of erythrocyte protoporphyrin is most useful in settings where iron deficiency levels are common and where infections, lead poisoning and other forms of anaemia are rare.

Until recently, erythrocyte protoporphyrin was measured by a complex and costly procedure that limited its use to that of a reference method. A simplified haematofluorometer that directly measures erythrocyte protoporphyrin fluorescence is now available. This device has enabled the widespread use of erythrocyte protoporphyrin testing in outpatient settings in the USA (100).

The severity of iron deficiency on the basis of erythrocyte protoporphyrin measurement is reflected in Table 8, below. Erythrocyte protoporphyrin levels are considered normal if only mild iron depletion is present (i.e. with serum ferritin levels of 12-24 mg/l). In the absence of infection, measurement of erythrocyte protoporphyrin is the preferred method for detecting iron deficiency once serum ferritin drops below the cut-off value, indicating inadequate iron supply to tissues.

**Table 8. Changes in iron status by age group on the basis of erythrocyte protoporphyrin**

<table>
<thead>
<tr>
<th>Iron status</th>
<th>Erythrocyte protoporphyrin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt; 5 years of age</td>
</tr>
<tr>
<td>Iron overload or excess</td>
<td>Normal</td>
</tr>
<tr>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Mild iron deficiency without anaemia</td>
<td>Normal</td>
</tr>
<tr>
<td>Moderate iron deficiency without anaemia</td>
<td>&gt;70 µg/dl red blood cell &gt;2.6 µg/g haemoglobin &gt;61 mmol/mol haem</td>
</tr>
<tr>
<td>Severe iron deficiency with anaemia</td>
<td>&gt;70 µg/dl red blood cell &gt;2.6 µg/g haemoglobin &gt;61 mmol/mol haem</td>
</tr>
</tbody>
</table>
IRON DEFICIENCY ANAEMIA

7.2.3 Serum iron, transferrin, and transferrin saturation

Iron deficiency results in a reduction in serum iron (SI) levels, an elevation in transferrin (total iron-binding capacity [TIBC]) levels, and hence a net reduction in transferrin saturation (i.e. SI/TIBC). However, the diurnal variation both in serum iron and transferrin saturation is considerable. In addition, there is a marked overlap in these indices between normal and iron-deficient subjects. This overlap diminishes the usefulness of these indices in establishing or rejecting a diagnosis of iron deficiency.

Transferrin saturation is of great value, however, as the first screening step for hereditary haemochromatosis. Cut-off values of between 60% and 70% have been widely used for this purpose. In screening for iron deficiency, individuals with more marked anaemia (responding to iron therapy with a haemoglobin increase >20 g/l) usually have a transferrin saturation <16%.

7.2.4 Serum transferrin receptors

The measurement of serum transferrin receptors is a recent addition to the available selection of tests for iron deficiency. However, epidemiological studies have yielded limited information concerning the usefulness of this test in discriminating between iron-deficient and iron-replete subjects.

An increase in serum transferrin receptors is a sensitive response during the early development of iron deficiency. Serum transferrin receptor levels increase progressively as the supply of iron to the tissues becomes progressively more deficient (101).

Major advantages of measuring serum transferrin receptors involve the facts that the assay is not significantly affected by infection or inflammatory processes, and it does not vary with age, gender, or pregnancy (102, 103). However, serum transferrin receptor levels may be elevated when there is increased red cell production, turnover, or both, such as in the case of haemolytic anaemia (104).

There are several methods for measuring serum transferrin. The most commonly used method is based on the ELISA assay (enzyme-linked immunosorbant assay). The values obtained will vary according to the method used, however, since there is no uniform standard available for their measurement. Similarly, there is currently no universally agreed reference value for serum transferrin.
7.2.5 Red cell indices

Among all the red cell indices measured by electronic blood counters, mean corpuscular volume and mean corpuscular haemoglobin are the two most sensitive indices of iron deficiency. Reduction in mean corpuscular volume occurring in parallel with anaemia is a late phenomenon in the development of iron deficiency. Reference values for mean corpuscular volume and mean corpuscular haemoglobin are presented in Table A5 in Annex 3.

7.2.6 Bone marrow iron stain

A bone marrow stain for iron has been regarded as the reference against which to evaluate other iron tests. Absence of stainable iron reflects absent iron stores. For this reason, the bone marrow stain correlates best with serum ferritin, which is another measure of iron stores (105). For obvious reasons, bone marrow iron-staining is not useful in simple population-based surveys.

7.3 Defining iron deficiency when multiple indices are available

As shown in Tables 6-8 in this Chapter, and Tables A1-A5 in Annex 3, there are for different population groups generally accepted cut-off values to define “iron deficiency” for each specific test described in the preceding sections. As indicated above, however, each test has limitations in terms of its sensitivity and specificity.

The best indicator for detecting iron deficiency is serum ferritin when measured in the absence of infection. Under the same conditions, elevated erythrocyte protoporphyrin indicates iron-deficient erythropoiesis or elevated levels of lead. However, erythrocyte protoporphyrin is less specific than serum ferritin. Transferrin saturation is even less reliable as an indicator of iron deficiency because of intra- and inter-day variability in serum iron. Mean corpuscular haemoglobin begins to decrease when iron reserves are depleted and iron deficiency has developed. However, mean corpuscular haemoglobin may not reach abnormally low levels until some time after iron deficiency sets in.

As a consequence of the limitations of each test, when they are considered jointly to define iron deficiency, sensitivity is low although specificity increases. Examples of such joint consideration include the model based on low transferrin saturation and high erythrocyte protoporphyrin, and the ferritin model based on low serum ferritin and transferrin saturation and high erythrocyte protoporphyrin.
These models underestimate iron deficiency as observed by haemoglobin response to iron administration. They therefore present no advantage over measurement of serum ferritin for diagnosing iron deficiency in populations.

A definition of iron deficiency based on multiple indicators is useful for population-based assessment when it is feasible to measure several indices. The best combination would be haemoglobin, serum transferrin receptors, and serum ferritin or bone-marrow iron. Such a combination would reflect functional impairment, tissue avidity for iron, and iron storage, respectively. Usually, this approach is not feasible in settings with resource constraints (see Table 5).

### 7.4 Haemoglobin response to iron and other supplements or interventions

One established approach to the diagnosis of iron deficiency in individuals or populations involves monitoring changes in haemoglobin or haematocrit after oral iron supplementation (106). An increase of at least 10 g/l in haemoglobin or 0.03 l/l in haematocrit after 1 or 2 months of supplementation is indicative of iron deficiency.

In settings where there are multiple causes of anaemia, iron supplementation may only partially correct the haematological deficit. For example, a combined iron and vitamin A supplement for pregnant women in Indonesia was needed where both deficiencies were common (107). Table 9 shows the response according to the combination of supplements given.

**Table 9. Proportion of anaemic pregnant women who responded to oral iron and vitamin A supplements and became non-anaemic**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Number of subjects</th>
<th>Anaemic cases that responded (haemoglobin &gt;110 g/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>62</td>
<td>16%</td>
</tr>
<tr>
<td>Vitamin A only</td>
<td>63</td>
<td>35%</td>
</tr>
<tr>
<td>Iron only</td>
<td>63</td>
<td>68%</td>
</tr>
<tr>
<td>Iron and vitamin A</td>
<td>63</td>
<td>97%</td>
</tr>
</tbody>
</table>

Source: Suharno et al. (107)
This Indonesian example illustrates the importance of assessing the potential multiple etiology of anaemia. This is necessary in populations with a high prevalence of possible etiologic factors, in order to decide whether multiple interventions are needed concurrently. These concurrent interventions may involve the use of other micronutrients in addition to iron; or the control of malaria, hookworm, or other infections; or both.

7.5 Assessing population iron status by using haemoglobin distributions

Estimates of haemoglobin are commonly included in nutrition surveys of children, whereas surveys specific for anaemia usually examine both children and women. The prevalence of anaemia serves as an index of the severity of iron deficiency in the whole population.

Where multiple factors may contribute significantly to anaemia, it is possible to differentiate anaemia attributable to iron deficiency from anaemia due to other factors. The latter include deficiencies of folic acid, vitamins A, B\textsubscript{12}, and C; or infections including malaria, hookworm, and schistosomiasis. This differentiation can be achieved by observing blood smears, by means of a small supplementation trial, or by conducting specific tests.

Where poor availability of dietary iron is the main etiologic factor, children and women are disproportionately affected, while the haemoglobin levels of adult men are virtually unaffected. Where other factors contribute significantly, adult men are less likely to be spared.

A useful approach involves comparison of the haemoglobin distribution among children, women, and men from the population under study with a non-anaemic reference population. This approach allows inferences to be made as to which factors are likely to be responsible for a high anaemia prevalence.

One example involves the comparison of haemoglobin distributions among children, women, and men in a Palestinian refugee population in which iron deficiency was the sole cause of anaemia. Another involves an Ethiopian refugee population in which a combination of both iron and vitamin C deficiencies coexisted, with the vitamin C deficiency affecting men as well as women and children. Figures 3a and 3b \cite{78} on the following two pages compare the haemoglobin distributions for each of these two refugee populations with US reference distributions.
Figure 3a. Haemoglobin distribution in Palestinian vs US children, women, and men

Source: Yip (78)
Figure 3b. Haemoglobin distribution in Ethiopian vs US children, women, and men

Source: Yip (78)
Iron deficiency, like most nutritional deficiencies of public health concern, is mainly a consequence of poverty. Even in developed countries, it affects a significant proportion of people in groups which are particularly vulnerable.

Prevention strategies must, if they are to be sustainable, involve the input and resources of a wide range of sectors and organizations. This is especially true for iron deficiency. For example, the agriculture, health, commerce, industry, education, and communication sectors should be included in any strategy. These, in turn, should work in concert with communities and with local nongovernmental organizations.

Efforts should be targeted to:

- reduce poverty;
- improve access to diversified diets;
- improve health services and sanitation; and
- promote better care and feeding practices.

These are fundamental elements of any programme to improve nutritional well-being in general, but are especially important in the improvement of iron status in particular.

### 8.1 Food-based approaches

#### 8.1.1 Dietary improvement

Food-based approaches represent the most desirable and sustainable method of preventing micronutrient malnutrition. Such approaches are designed to increase micronutrient intake through the diet.
Food-based approaches should therefore include strategies to:

- improve the year-round availability of micronutrient-rich foods;
- ensure the access of households, especially those at risk, to these foods; and
- change feeding practices with respect to these foods.

One of the greatest strengths of these food-based strategies lies in their potential to result in multiple nutritional benefits. These benefits can, in turn, achieve both short-term impact and long-term sustainability.

In practice, food-based approaches should first address the production, preservation, processing, marketing, and preparation of food. Secondly, they should address feeding practices, such as intra-family food distribution and care for vulnerable groups.

Applied to iron deficiency, efforts should be directed towards promoting the availability of, and access to, iron-rich foods. Examples include meat and organs from cattle, fowl, fish, and poultry; and non-animal foods such as legumes and green leafy vegetables.

Similarly, focus should be upon foods which enhance the absorption or utilization of iron. Examples include those of animal origin, and non-animal foods - such as some fruits, vegetables, and tubers - that are good sources of vitamins A and C, and folic acid. Finally, effective nutrition education - and information on health and nutrition for both supply and demand aspects of programmes - may be needed to increase the demand for and consumption of such foods.

The first step in this process involves obtaining and analysing information on the various foods consumed and on the way they are processed, mixed, and prepared for a meal. Annex 4 suggests proposed strategies for obtaining such information, adapted from the approach currently used with success in some programmes to promote consumption of foods rich in vitamin A.

The interpretation of values concerning iron status which have been obtained using this methodology will vary according to the bioavailability of iron from local food mixtures and meal patterns. Accordingly, this approach should be adapted to, and its value assessed under, local conditions.
Once all the information has been analysed, appropriate recommendations can be made for changing dietary components and the timing of their consumption, altering food processing or preparation, or changing meal patterns. The focus should be on changes that will improve the bioavailability, as well as the amount, of iron in the diet.

Interpretation of bioavailability is limited by the scarcity of accurate information concerning the content of phytates and iron-binding polyphenols in various foods. Such information is urgently needed to facilitate the promotion of correct food choices.

Recommendations should be adapted to regional and local variations in diet, the age group concerned, seasonal availability, and other factors that cause food intake and meal patterns to vary. It should be noted that food-frequency questionnaires are not a sufficient base from which to draw inferences on likely iron status unless they are combined with information on meal composition and food consumption patterns.

Methods of food preparation and processing influence the bioavailability of iron. Cooking, fermentation, or germination can, by thermal or enzymatic action, reduce the phytic acid and the hexa- and penta-inositol phosphate content. All inositol phosphates inhibit iron absorption in proportion to the total number of phosphate groups. Processing procedures that lower the number of phosphate groups improve bioavailability of non-haem iron (108).

Building food-based approaches around the needs and activities of women can be especially effective. This is particularly important in recognition of the multiple roles women play as food providers and primary caregivers.

For example, promoting home gardens and small animal husbandry, and improving food preservation and home or community processing technologies, can be especially useful in improving iron status. These interventions are enhanced by efforts to generate additional income for women and by effective nutrition education.

The primary goal of dietary modification to improve and maintain the iron status of a population involves changes in behaviour, leading to an increase in the selection of iron-containing foods and a meal pattern favourable to increased bioavailability. Although sometimes difficult to achieve, such changes in dietary habits can bring about important sustainable improvements, not only in iron status but also for nutrition in general. Such changes must be rooted in issues that take into account food security, actual availability, and education.
Bioavailability of food iron is strongly influenced by enhancers and inhibitors in the diet. Presently, there is no satisfactory \textit{in vitro} method for predicting the bioavailability of iron in a meal.

Iron absorption can vary from 1% to 40%, depending on the mix of enhancers and inhibitors in the meal. Therefore, the adequacy - i.e. bioavailability - of iron in usual diets can be improved by altering meal patterns to favour enhancers, lower inhibitors, or both.

\textbf{Enhancers} of iron absorption include:

- haem iron, present in meat, poultry, fish, and seafood;
- ascorbic acid or vitamin C, present in fruits, juices, potatoes and some other tubers, and other vegetables such as green leaves, cauliflower, and cabbage; and
- some fermented or germinated food and condiments, such as sauerkraut and soy sauce (note that cooking, fermentation, or germination of food reduces the amount of phytates).

\textbf{Inhibitors} of iron absorption include:

- phytates, present in cereal bran, cereal grains, high-extraction flour, legumes, nuts, and seeds;
- food with high inositol content;
- iron-binding phenolic compounds (tannins); foods that contain the most potent inhibitors resistant to the influence of enhancers include tea, coffee, cocoa, herbal infusions in general, certain spices (e.g. oregano), and some vegetables; and
- calcium, particularly from milk and milk products.
Examples of simple but effective alterations in meal patterns that enhance iron absorption might include:

- separate tea drinking from mealtime - one or two hours later, the tea will not inhibit iron absorption because most of the food will have left the stomach;

- include in the meal fruit juices such as orange juice, or another source of ascorbic acid such as tubers, cabbage, carrots, or cauliflower;

- consume milk, cheese, and other dairy products as a between-meal snack, rather than at mealtime; and

- consume foods containing inhibitors at meals lowest in iron content, e.g. a breakfast of a low-iron cereal (bread or corn tortilla) consumed with tea or milk products; this meal pattern can provide adequate calcium without hampering iron nutrition.

Other actions that indirectly affect iron status might include:

- parasitic disease control programmes, in particular those directed to hookworm, schistosomiasis and malaria control; these programmes can enhance iron deficiency anaemia control programme effectiveness in a population with moderate to severe levels of infection; and

- incentive policies and improved farming systems that favour the development, availability, distribution, and use of foods that enhance iron absorption.
Iron Deficiency Anaemia

A step-by-step practical approach, that might be followed in any setting, would be to:

- assess food availability and eating practices, and describe a typical daily meal pattern with emphasis on populations at highest risk;
- analyse the content of the foods and meals, in terms of iron and potential enhancers and inhibitors;
- estimate bioavailability (109);
- determine ways in which nutritional status can be modified, through composition of meals (given local food availability, costs, and cultural factors); timing of the consumption of certain foods; and food preparation practices;
- implement appropriate dietary modifications; and
- assess iron status (haemoglobin or haematocrit levels) before and after implementing modified practices.

Indicators of the progress of programme implementation through dietary improvement should be developed and interpreted locally and nationally. These indicators should be periodically reviewed and adapted to reflect changing programme needs. The indicators should be simple and inexpensive, in order to be feasible. One or two indicators to monitor each primary type of intervention are likely to be sufficient. Rapid appraisal techniques are often appropriate for this purpose.

8.1.2 Food fortification

There is a consensus that enrichment (or fortification) of food is an effective long-term approach to improving the iron status of populations. Once a fortification programme is established, it is a cost-effective and sustainable means of achieving this purpose. The technical, operational, and financial feasibility should, however, be carefully assessed before embarking on such a fortification programme.

An effective iron fortification programme requires the cooperative efforts of governments, the food industry (producers, processors, and marketers) and consumers. Appropriate food vehicles and fortificants must be selected.
Legislation that permits, regulates, or requires the addition of iron fortificants to foods is essential, as are effective enforcement mechanisms. Legislative action to ensure the quality and safety of iron-fortified foods, and honest and fair practices in marketing them, may also be needed.

Essential requirements for implementing fortification strategies include the identification of an appropriate food vehicle that reaches the target population, that is centrally processed, and that is widely available and consumed in relatively predictable amounts by vulnerable population groups. It is essential that the final product not be significantly changed in terms of its organoleptic quality, shelf life, or price; and that the food as prepared be acceptable to the population.

The dietary habits of the population are an important consideration in selecting a food for fortification. For example, possible appropriate food vehicles range from wheat flour or pasta and condiments like sugar, salt, curry powder, haldi, monosodium glutamate (MSG), to bouillon cubes and soy sauce.

In subsistence farming areas in most developing countries, a fortified-food approach has limited potential because few households ever consume commercially processed foods. Instead, fortified food supplements can be effectively and widely distributed through general food distribution programmes, e.g. school lunch or other supplemental or emergency feeding programmes.

Several iron fortificants have been used successfully in a variety of national programmes. Examples are as follows.

- Rice in the Philippines is fortified with a standard ferrous sulphate mix.

- Where bread and pasta are abundantly consumed, and flour is milled in only a few places, several iron fortificants have been added successfully during the milling process. Ferrous sulphate is adequate if the turnaround time between milling and bread consumption is relatively short (3 to 4 months), as in Chile.

- If flour (wheat or maize) is stored for a long time, metallic iron (Sweden, UK, and USA) or ferrous fumarate (Venezuela) have been used. When flour is used as a vehicle, the general population is the target group, but this approach does not reach infants and young children, who usually consume little bread.
Iron-EDTA

Sodium iron ethylenediaminetetraacetic acid (NaFeEDTA), known as iron-EDTA, is a potentially valuable fortificant that has hitherto had limited use. Compared to other fortificants, it is better absorbed and not sensitive to many food iron inhibitors. Accordingly, it is particularly interesting in populations whose staple foods are based on cereals and legumes.

Because iron-EDTA is well absorbed and not reactive, it does not cause fat (e.g. in bread) to become rancid. Therefore, it is suitable for use in other (not previously fortified) foods. It is also chemically stable, which allows for long storage of foods. Condiments such as curry powder in South Africa have been successfully fortified with iron-EDTA, as has sugar in Guatemala (110). However, additional information is needed on its efficacy and safety before it can be recommended.

Studies on multiple fortification have been boosted by the advent of several new technologies including the development of iron-EDTA. Double fortification with iron-EDTA and vitamin A in Guatemala (110) and with iodide and metallic iron in India (111) has already been examined.

The concern that iron-EDTA might inhibit bioavailability (i.e. that it might promote the loss) of other minerals such as zinc or calcium, is allayed by studies in humans with stable isotope tracers (112). In a long-term study in Guatemala, zinc blood levels actually rose after 30 months following the consumption of iron-EDTA fortified sugar (110).

In fact, other animal and human data confirm improved absorption of zinc-iron-EDTA. However, further research is necessary to understand how iron-EDTA interacts with other micronutrients.

In some industrialized countries, EDTA has been extensively used as a stabilizer. The Joint FAO/WHO Expert Committee on Food Additives (JECFA) examined the existing data on iron-EDTA and found no objection to its use at a level of 2.5 mg/kg of body weight per day (113).

Fortified foods for young children

Normal-birth-weight infants who are exclusively breastfed do not need iron supplements for the first 4 to 6 months of life. When complementary feeding begins, and certainly after 6 months of age, infants need an additional source of iron to maintain adequate iron nutrition and prevent iron deficiency anaemia.
Since cereals are widely used as early complementary foods, they should be fortified during their commercial preparation, by extrusion, cooking, or mixing processes. Centrally processed milk-based foods designed for infants and preschool children should also be fortified. Other forms of iron have been used for infant cereals: small-particle-size metallic iron is the form most widely used.

An iron complex with ammonium-orthophosphate - which is less reactive and has better absorbability - is used successfully in Sweden, and its use should be explored elsewhere. Iron pyrophosphate and orthophosphate should not be used, because of their poor bioavailability.

Finally, the practice of including iron-rich complementary foods for young children should be encouraged, both at home and in the community. Ferrous sulphate is the most widely used fortificant for cows’ milk or modified infant formula.

**Emergency foods**

In emergency situations, the provision of food supplements that are adequate in energy and protein but not in essential micronutrients, may provoke or aggravate micronutrient deficiencies. For example, while the growth of young children may be enhanced, without provision of the additional micronutrients needed to support that growth, clinical deficiencies may be precipitated.

As recommended by the WHO/FAO International Conference on Nutrition (Rome, 1992), the nutrient content of emergency food aid for refugees and displaced persons should

> meet the nutritional requirements, if necessary through fortification or ultimately through supplementation. Governments, in collaboration with the international community, should provide sustainable assistance to refugees and displaced persons, giving high priority to the prevention of malnutrition and the outbreak of micronutrient deficiency diseases.

Such fortification might include not only iron, but also vitamins A, C, or both, the B vitamins, iodine, and other nutrients, depending on the anticipated risk of these deficiencies and based upon local circumstances. However, the cost of providing fortified foods is high - if funds are limited, their use for this purpose might entail a reduction of overall food supplies available for distribution, as well as delays in delivery.
Food aid

When supplemental foods are used under normal conditions, as for example in food-for-work or supplementary feeding programmes, they should be fortified with iron to prevent the risk of deficiency. The World Food Programme provides vitamin A-fortified skimmed milk and iodized salt in countries with populations at risk of these deficiencies. Cereal-legume blends, including corn-soy-milk and wheat-soy, are also commonly fortified with minerals and vitamins.

Few governments have a clear policy or programme for dietary improvement or food fortification to alleviate iron deficiency. In view of the new knowledge and technologies available, it is timely for all countries whose population is affected by iron deficiency - and who have not yet defined a food-based strategy - to undertake a feasibility study of the possibilities for dietary improvement and food fortification (114).

8.2 Iron supplementation

Iron supplementation is the most common strategy currently used to control iron deficiency in developing countries. This is likely to remain the case until either significant improvements are made in the diets of entire populations or food fortification is achieved.

Supplementation is most often used to treat existing iron deficiency anaemia. It should also be considered as a preventive public health measure to control iron deficiency in populations at high risk of iron deficiency and anaemia. Supplementation programmes, especially for pregnant women, operate in developed as well as in developing countries. For example, Sweden has been implementing iron supplementation and fortification of many foods for many years. This practice may explain a relatively low prevalence of iron deficiency anaemia in that country.

Various delivery systems and modalities, under conditions of varied efficiency, reach a wide range of target groups. Small controlled studies of supplementation have been shown to be particularly successful, and a few large-scale supplementation programmes clearly demonstrating positive biological impact are reported from some developing countries. Countries should identify specific problems and constraints limiting the effectiveness of supplementation programmes and those key elements responsible for successes and failures. Only then will information be sufficient to introduce effective and efficient solutions, if traditional approaches and practices are to continue.
Traditionally, target groups for supplementation programmes have been pregnant women and infants. This practice is due to the short- and long-term health benefits of these programmes for both groups. To a large extent, they are reached with relative ease through the health system in urban areas.

However, it has become increasingly evident that the main target group for supplementation to prevent iron deficiency should be all women of childbearing age (in addition to infants older than 6 months, preschool children, and adolescent girls). This target group should not be limited to pregnant women, who are often accessible only through the health system and late in pregnancy.

One problem is that all of these groups are often difficult to contact through the health services. An exception involves adolescent girls, who may be reached through the school system.

Therefore, efforts should concentrate on supplementation programmes for women of childbearing age. If women enter pregnancy with adequate iron reserves, iron supplements provided during pregnancy will be more efficient at improving the iron status of the mother and of the fetus. As a result, the risk of maternal anaemia at delivery and of anaemia in early infancy will be reduced.

### 8.2.1 Iron supplementation to prevent iron deficiency anaemia

It is important to differentiate between supplementation that aims at preventing anaemia by correcting iron deficiency before iron deficiency anaemia is manifest, and therapeutic supplementation, which aims at correcting established iron deficiency anaemia (115).

Therapeutic supplementation should be part of the health care delivery system. Supplementation to prevent iron deficiency without anaemia may be a community-based initiative which needs innovative approaches in order to deliver timely preventive supplements to groups at risk.

Women’s organizations, schools, and religious and community leaders are all potentially important players in delivering supplements to correct iron deficiency. Approaches based on self-purchase of supplements through community stores should also be evaluated.

Several trials utilizing supplements on a weekly - rather than daily - basis are now in progress (116, 117). However, the demonstrated effectiveness of weekly programmes, based on self-administered iron supplements under programme conditions, is awaited before being recommended as a public health measure.
<table>
<thead>
<tr>
<th>Age groups</th>
<th>Indications for supplementation</th>
<th>Dosage schedule</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-birth-weight infants</td>
<td>Universal supplementation</td>
<td>Iron: 2 mg/kg body weight/day</td>
<td>From 2 months of age up to 23 months of age</td>
</tr>
<tr>
<td>Children from 6 to 23 months of age</td>
<td>Where the diet does not include foods fortified with iron or where anaemia prevalence is above 40%</td>
<td>Iron: 2 mg/kg body weight/day</td>
<td>From 6 months of age up to 23 months of age</td>
</tr>
<tr>
<td>Children from 24 to 59 months of age</td>
<td>Where anaemia prevalence is above 40 %</td>
<td>Iron: 2 mg/kg body weight/day up to 30 mg</td>
<td>3 months</td>
</tr>
<tr>
<td>School-aged children (above 60 months)</td>
<td>Where anaemia prevalence is above 40 %</td>
<td>Iron: 30 mg/day Folic acid: 250 µg/day</td>
<td>3 months</td>
</tr>
<tr>
<td>Women of childbearing age</td>
<td>Where anaemia prevalence is above 40 %</td>
<td>Iron: 60 mg/day Folic acid: 400 µg/day</td>
<td>3 months</td>
</tr>
<tr>
<td>Pregnant women</td>
<td>Universal supplementation</td>
<td>Iron: 60 mg/day Folic acid: 400 µg/day</td>
<td>As soon as possible after gestation starts - no later than the 3rd month - and continuing for the rest of pregnancy</td>
</tr>
<tr>
<td>Lactating women</td>
<td>Where anaemia prevalence is above 40 %</td>
<td>Iron: 60 mg/day Folic acid: 400 µg/day</td>
<td>3 months post-partum</td>
</tr>
</tbody>
</table>

**Table 10. Dosage schedules for iron supplementation to prevent iron deficiency anaemia**
**Dosage schedules for iron supplementation (Table 10, opposite)**

**Low-birth-weight infants**

A daily dosage of 2 mg iron/kg of body weight in the form of a liquid preparation should be given to all low-birth-weight infants, starting at 2 months and continuing to 23 months of age (universal supplementation).

**Infants and children below 2 years of age**

Where the diet does not include fortified foods, or prevalence of anaemia in children approximately 1 year of age is severe (above 40%), supplements of iron at a dosage of 2 mg/kg of body weight/day should be given to all children between 6 and 23 months of age. There have been some reports of stained teeth after iron supplementation with some solutions. Good oral hygiene and the use of ferrous carbonate can prevent this condition. Ferrous carbonate is not soluble, but present as a suspension or a solution of iron-EDTA (118).

**Children above 2 years of age**

The recommended WHO regimen (4) - based on daily supplementation as summarized in Table 10 - should be followed. However, supervised weekly, or biweekly supplementation of preschool and school-aged children and adolescent girls has been reported to be effective in several countries (115,119,120).

**Women of childbearing age: pregnant women**

A total amount of about 700-850 mg of iron is needed to meet the iron requirements of a mother and fetus during pregnancy, at delivery, and during the perinatal period. Iron needs during the first trimester are lower than pre-pregnancy needs; they increase the most during the second half of the pregnancy and especially during the last trimester. For unknown reasons, dietary iron absorption in iron-sufficient women is reduced during the first trimester and increased in the second half of pregnancy.

The average woman of reproductive-age needs about 350-500 mg additional iron to maintain iron balance during pregnancy. Potentially, this iron could be provided either from the mother’s iron stores or from iron supplements. However, it is not reasonable to expect that this additional iron can come from iron stores, since they very seldom reach this level in women in either developed or developing countries (the mean iron content of the body reserves - ferritin and haemosiderin - is often only around 200-250 mg).
Furthermore, in developing countries 25-30% of women have no iron reserves at all. Because the situation is especially serious among pregnant teenagers, it is important to promote all measures - with emphasis on pubertal girls - that will improve iron reserves before pregnancy.

All pregnant women (universal supplementation) should be given 60 mg iron and 400 µg folic acid daily during the second half of pregnancy to control iron deficiency anaemia. There is some evidence, however, that smaller doses of 30 mg daily could achieve similar results (86,121).

Combined with other micronutrients, folic acid should always be given with iron during pregnancy. This combination is important because of the increased folic acid requirement of pregnant women and the fact that both deficiencies are common in pregnancy. In addition, folic acid supplementation prior to pregnancy will also have an impact on maternal folic acid status, which is expected to reduce the risk of neural tube defects (120).

**Women of childbearing age: lactating women**

In populations with a severe prevalence of anaemia (>40%), it is recommended that iron supplementation begin during pregnancy. Supplementation should continue during lactation for at least three months post-partum, at the same dosage - 60 mg iron and 400 µg folic acid daily - as during pregnancy.

**Women of childbearing age: non-pregnant women**

In areas where the prevalence of anaemia among women of childbearing age is severe (> 40%), preventive iron supplementation of 60 mg/day iron with 400 µg folic acid for 3 months should be considered.

**Adolescents**

Where prevalence of anaemia in pubertal girls is severe (>40%), preventive iron supplementation of 60 mg/day iron with 400 µg folic acid for 3 months should be considered. Adolescent boys should also receive preventive iron supplementation where prevalence of anaemia among them is severe (>40%). As with adolescent girls, supplementation should continue throughout adolescence, following the same schedule of 60 mg/day iron with 400 µg folic acid for 3 months.
8.2.2 Problems associated with iron supplementation

Delivery system

Much of the success of an iron supplementation programme depends on the effectiveness of the delivery system. The framework of the programme will be provided by the health system of the country in question. It may also include primary health care facilities and community health workers, such as traditional birth attendants and volunteers (121). Ideally, iron supplementation should be community-based: the community should embrace the need for the programme and provide support on its behalf.

To this end, involving other human resources in the community should be seriously considered. These include the school system, women’s clubs, religious organizations, and nongovernmental organizations, together with formal and informal community leaders. Involvement and participation of the private health system will also help to achieve maximum coverage.

Adherence

Irregular consumption of prescribed iron supplements, due in part to side-effects (Table 11), has plagued most supplementation programmes. For this reason, definitive results of tests of iron preparations with fewer side-effects are eagerly awaited. Even if new iron preparations are more expensive than ferrous sulphate, they may ultimately be more cost-effective if they improve adherence (122).

Table 11. Possible side-effects associated with iron medication

- Epigastric discomfort, nausea, diarrhoea, or constipation may appear with a daily dose of 60 mg or more. If these symptoms occur, supplement should be taken with meals.

- Faeces may turn black, which is not harmful. Treatment should continue.

- All iron preparations inhibit the absorption of tetracyclines, sulphonamides, and trimethoprim. Thus, iron should not be given together with these agents.

- High-dose vitamin C supplements should not be taken with iron tablets, because this would likely cause epigastric pain.
IRON DEFICIENCY ANAEMIA

The side-effects of iron tablets generally increase with higher dosages. These side-effects can be reduced if supplements are taken with meals, but absorption is reduced by about 40% (125). If the supplement is administered in the form of a single tablet, it is best ingested at bedtime.

Adherence frequently diminishes due to intolerance when more than one iron tablet of 60 mg is required. Under such circumstances, prescribing one daily tablet instead of two is justified as a general policy or for the particular subjects who experience intolerance. One tablet taken consistently is preferable to the risk of total rejection or non-acceptance of supplements.

Awareness and motivation

Motivating the target group to take iron tablets according to the prescribed schedule, thereby improving adherence, is of utmost importance. Accordingly, communities, families, mothers, and health workers need to be well informed about the health benefits - as well as the side-effects - of iron supplementation for both the mother and fetus.

One approach is a comprehensive education and information programme, organized through the health and other community infrastructures. Such a programme should emphasize the benefits of iron supplementation and provide advice concerning possible side-effects. Community leaders, volunteer health workers or local cadres, schoolteachers, and students can reinforce these messages as a demonstration of their involvement in and commitment to the community.

The training of community workers involved in programme implementation is essential. Social marketing techniques can be used to great advantage. Of course, the design of messages should take into account local terms, perceptions, and cultural factors related to anaemia.

Quality and packaging of iron supplements

Improvements are needed in the quality of iron tablets, especially in their stability (e.g. avoidance of cracking, and disintegration, and absorption of moisture) and other physical characteristics (e.g. their colour and odour). Development of improved packaging to minimize deterioration before distribution, and innovative and safe ways of dispensing the tablets, is also needed.

The design and testing of all of these aspects of iron supplementation are significant in improving adherence. They are especially important in preventing accidental iron poisoning, particularly in children.
Risk of iron overload with iron supplementation

The above-mentioned supplementation strategies are not considered to be associated with any increased risk of iron overload (see Annex 2).

Monitoring and evaluation

Iron supplementation programmes should be carefully assessed, and their efficiency and effectiveness monitored, to improve critical aspects of the system.

8.2.3 Other complementary public health interventions

Iron supplementation programmes should be integrated into broader public health programmes which are directed to the same population target groups. Iron supplementation during pregnancy and lactation is a major component in reducing maternal morbidity and mortality. Emphasis should therefore be placed upon increasing the capacity of antenatal, postnatal, and child health clinics to provide iron supplementation for mothers and children.

For maximum effectiveness, links should be established with programmes such as those targeting:

- malaria prophylaxis;
- hookworm control;
- immunization;
- environmental health;
- control of micronutrient malnutrition; and
- community-based primary health care.

Community participation within the framework of the concept of primary health care (and beyond) should be actively encouraged.
8.2.4 Integration with other micronutrient control programmes

Preventive supplementation is particularly well-suited to strategies that combine multiple micronutrient interventions. Accordingly, efforts should be intensively directed to this area. Programmes that involve preparations containing iron, folic acid, and vitamins A and C, directed to infants, children, and pregnant and lactating women, are highly desirable.

Similarly, much more attention should be focused on the use of multiple micronutrient-fortified food preparations in supervised feeding programmes (e.g. in schools and emergency situations). The involvement in this effort of the pharmaceutical and food industries and of food-aid donors should be fostered. Also encouraged should be the active participation of educational institutions, such as home-science colleges and departments.

In emergency situations (e.g. among refugees, displaced, or war-affected populations) infants and young children are particularly vulnerable to iron and other micronutrient deficiencies. Food aid provided in these situations should be nutritionally adequate to prevent iron deficiency anaemia and other micronutrient deficiency disorders.

To determine appropriate complementary action in micronutrient programmes, it is necessary to conduct a careful analysis based on a conceptual framework that compares:

- the etiology of each micronutrient deficiency;
- vulnerable groups;
- groups most appropriate for assessment and monitoring purposes (surveillance groups); and
- suitable intervention strategies.

Table 12 compares complementary actions involving the three micronutrient deficiencies currently of major public health significance, i.e. iodine, iron, and vitamin A. Combined approaches to overcoming micronutrient malnutrition - especially deficiencies in vitamin A and C, folic acid, iron, and zinc - should be emphasized (105,124,125), especially since the foods to be promoted and other necessary actions are often similar for these nutrients.
### Table 12. Iodine, iron and vitamin A deficiencies: etiology, vulnerable groups, and appropriate groups for surveillance purposes

<table>
<thead>
<tr>
<th>Iodine deficiency</th>
<th>Iron deficiency</th>
<th>Vitamin A deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Etiology</strong></td>
<td>Dietary</td>
<td>Dietary</td>
</tr>
<tr>
<td>Geographic</td>
<td>Increased losses</td>
<td>Increased losses</td>
</tr>
<tr>
<td><strong>Vulnerable groups</strong></td>
<td>Pregnant and lactating women</td>
<td>Pregnant and lactating women</td>
</tr>
<tr>
<td>Entire population</td>
<td>Infants</td>
<td>Infants less than 6 months old</td>
</tr>
<tr>
<td></td>
<td>Preschool children</td>
<td>Preschool children</td>
</tr>
<tr>
<td></td>
<td>Women of childbearing age, including adolescent girls</td>
<td></td>
</tr>
<tr>
<td><strong>Surveillance groups</strong></td>
<td>Pregnant women</td>
<td>Preschool children</td>
</tr>
<tr>
<td>School-aged children</td>
<td>Preschool children</td>
<td>Preschool children</td>
</tr>
</tbody>
</table>

#### 8.2.5 Iron supplementation to correct iron deficiency anaemia

As mentioned earlier in this chapter, it is important to differentiate between supplementation for the *prevention* of iron deficiency anaemia and supplementation for its *correction*. The amounts of iron supplementation recommended to treat iron deficiency anaemia for adults is 120 mg/day iron for 3 months. For infants and younger children, it is 3 mg/kg/day, not to exceed 60 mg daily.
This chapter identifies needs for action-oriented research in the fields of iron deficiency and anaemia. These research needs are presented in relation to the various intervention strategies described in the preceding chapters.

**9.1 Dietary improvement**

- Develop simple methods of dietary assessment, including screening foods or meals for their value as important sources of bioavailable iron and other nutrients.
- Develop laboratory methods for assessing iron bioavailability from individual meals.
- Update analytical databases on food, condiments, and spices, with respect to iron content and availability, as well as content of folic acid, vitamin C, tannins, phytates, vitamin A, and carotenoids.
- Evaluate traditional forms of food preparation that may favourably affect bioavailability of iron, which are decreasing in use (e.g. fermentation); and explore ways in which these methods can be made more practical and/or less time-consuming.
- Investigate methods of improving dietary patterns (e.g. food selection and preparation, addition of enhancers or removal of inhibitors of iron absorption).
- Research practical methods of food preparation that will reduce the content of tannins and phytates, such as the use of commercial phytase, malting of cereals, prolonged cooking at high and low temperatures, germination and fermentation.
Expand knowledge about interactions among and between nutrients and/or non-nutrient factors (e.g. condiments and vitamins A and C, which influence micronutrient bioavailability, especially that of iron).

Conduct operational research to improve community nutrition and related education, and implement a social marketing approach with the ultimate goal of improving the quality and quantity of the food supply and its use.

Explore methods of introducing adventitious iron sources, such as the use of iron cooking pots.

Evaluate approaches to improving the delivery and adoption of agricultural inputs and technologies by nutritionally vulnerable or iron-deficit households.

Develop means to extend outreach to women farmers through agriculture extension services.

Explore methodologies for improving the marketing of foods rich in iron and vitamins A and C.

Improve methods for documenting the cost-effectiveness of horticultural interventions.

9.2 **Iron fortification**

Expand research on iron-EDTA to include not only its current areas of application, but also its use in non-traditional vehicles (e.g. an adequate fortificant, its effect on absorption of other minerals, and the effectiveness of its absorption to influence meal iron bioavailability compared with that from ferrous sulphate).

Continue research to determine how EDTA promotes the absorption of the non-haem iron pool.
Continue to explore the potential for multiple fortification of foods with micronutrients.

Improve fortification technology to make fortification feasible in remote areas and in the community (e.g. premixes for home fortification use and microencapsulation).

Conduct pilot fortification studies to assess biological effectiveness, acceptability, and costs.

Develop methods for quality assurance control of fortification.

### 9.3 Iron supplementation

- Assess relative effectiveness of weekly supplements in various vulnerable population groups and under various conditions of programme implementation.

- Conduct operational research on ways to improve the effectiveness and efficiency of preventive and therapeutic iron supplementation programmes.

- Explore new approaches to iron supplementation, which may have better absorption and fewer side-effects.

- Determine the cost-effectiveness of universal supplementation of infants in areas where a high prevalence of iron deficiency is found among them.

- Conduct operational research on practical surveillance systems, use of sentinel sites, etc.

- Undertake operational research on community-based infrastructures for the distribution of iron and folic acid to pregnant women, and monitoring its effects among them.
Study effects of zinc supplementation in areas where iron deficiency is highly prevalent.

Conduct bioavailability tests on preparations containing multiple micronutrients.

Study combined pharmaceutical micronutrient preparations and super-fortified foods, including their feasibility, stability, and effectiveness.

Study the role, effectiveness, and cost-effectiveness of treating hookworm infections as a means of alleviating or preventing anaemia and iron deficiency.
In order to reduce substantially the prevalence of iron deficiency anaemia, and in support of national programmes for the prevention of iron deficiency, the following actions are recommended:

10.1 For governments

- Undertake appropriate studies to collect or update information on the prevalence and severity of anaemia in various age groups and by gender in the principal ecological zones and socioeconomic groups of the country; results should be made rapidly available and used as the basis for advocacy and programme planning and monitoring.

- Formulate and implement, as part of the national plan of action for nutrition, a programme for the prevention of iron deficiency, based on a combination of dietary improvement, food fortification (where feasible) and iron supplementation; public health measures integrated into maternal and child health, and primary health care programmes as described in Annex 5, should also be part of the plan.

- Establish a surveillance system to ensure appropriate monitoring of iron status and of programme implementation, using indicators outlined in this report; locally applicable programme indicators should be further developed.

- Undertake a feasibility study of iron fortification programmes with emphasis upon reaching at least the major vulnerable populations.
Review, and strengthen as necessary, national legislation or regulations dealing with fortification and the marketing of appropriate fortified foods; strengthen appropriate food control and quality assurance systems; and foster effective working relationships with the food industry and consumer groups.

Develop appropriate support activities, e.g. human resources development (training of programme managers, sector specialists, extension agents, and laboratory and field staff, each for his or her respective role); advocacy; information, education, and communication; and applied research; and provide at least the minimum facilities necessary to those activities, including those for anaemia assessment.

Develop suitable managerial mechanisms, including integration into appropriate community programmes, e.g. those promoting sustainable agriculture and rural development, primary health care, maternal and child health, and prevention of other micronutrient deficiencies.

Mobilize the effective participation of community groups, the private sector, and nongovernmental organizations, in these programmes.

10.2 For supporting organizations and institutions

Stimulate and provide technical, material, and financial support for the formulation, implementation, and monitoring and evaluation of national and local programmes.

Assist in mobilizing and training necessary human resources.
IRON DEFICIENCY ANAEMIA

- Provide support for appropriate applied and operational research.

- Ensure the organization of necessary global, regional, and subregional advocacy, and of appropriate meetings, communications, and information systems.

- Develop rosters of available human resources in various categories, and in all countries, and ensure the widespread circulation of those rosters.

- Initiate, if possible, systems for continuous collection and periodic dissemination of information on the prevention of iron deficiency, and systems to ensure adequate communication on iron deficiency prevention initiatives, especially through widely circulated periodicals, bulletins, and newsletters.

- Ensure that adequate and appropriate global and national information systems are established in connection with iron deficiency, including information on the implementation of prevention programmes.

- Foster action-oriented research, and networking to increase collaborative efforts and cross-cultural trials.